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phosphorylation (APH). APH(9)-Ia and ANT(3")(9) were expressed in E. coli BL21(DE3) and purified using
the Ni-affinity chromatography. The ability of AMEs to modify and inactivate amSPCs has been examined
by two unique biochemical assays, including an agar-based enzyme assay. Binding of APH (9)-Ia and ANT
(3")(9) to spectinomycin and amSPCs has been studied using Thermal Denaturation assay and
MicroScale Thermophoresis (MST).
The microbiological role of these enzymes has been examined by minimum inhibitory concentration
(MIC) shifts using an arabinose inducible expression of APH (9)-Ia and ANT (3")(9) in E.coli K12 and JW
ΔtolC strains. Our agar-based enzyme assay shows the inactivation of spectinomycin by APH(9)-Ia.
Phosphorylated spectinomycin and adenylated spectinomycin products upon incubation with APH(9)-Ia
and ANT(3",9), respectively, have been identified using MALDI-MS. APH(9)-Ia induction studies in E. coli
tolC knock-out strains reveal a MIC increase against spectinomycin in the presence of 2% arabinose
compared to no shift with amSPCs. ANT (3")(9) showed an increase in MIC against spectinomycin as well
as amSPCs. In conclusion, amSPCs are not inactivated by APH (9)-Ia in vivo but are inactivated by ANT
(3")(9). Most Gram-negative bacteria isolated in clinics possess one or more AMEs. By overcoming
modification by AMEs, amSPCs can be a valuable tool in overcoming resistance in Gram-negative
bacterial infections. We also conducted a high throughput screen of a polar small molecule library against
two multi-drug resistant clinical isolates of Escherichia coli that encode aminoglycoside modifying
enzyme for small molecule potentiators of amSPCs to yield 12 possible potentiating molecules that have
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ABSTRACT

Spectinomycin (SPC) is a broad-spectrum aminocyclitol antibiotic. Its use in
agriculture has led to widespread resistance in enteric bacteria, necessitating the
development of more effective analogs. Aminomethyl spectinomycins (amSPC) are
modified spectinomycins with increased potency against many bacterial species. These
species include Legionella pneumophila, which harbors a chromosomally encoded
aminoglycoside modifying enzyme (AME). In this study, we follow up on this
observation and examine the extent to which the amSPCs are substrates for AMEs
through adenylation (ANTs) and phosphorylation (APH). APH(9)-Ia and ANT(3")(9)
were expressed in E. coli BL21(DE3) and purified using the Ni-affinity chromatography.
The ability of AMEs to modify and inactivate amSPCs has been examined by two unique
biochemical assays, including an agar-based enzyme assay. Binding of APH (9)-Ia and
ANT (3")(9) to spectinomycin and amSPCs has been studied using Thermal Denaturation
assay and MicroScale Thermophoresis (MST).
The microbiological role of these enzymes has been examined by minimum
inhibitory concentration (MIC) shifts using an arabinose inducible expression of APH
(9)-Ia and ANT (3")(9) in E.coli K12 and JW ΔtolC strains. Our agar-based enzyme assay
shows the inactivation of spectinomycin by APH(9)-Ia. Phosphorylated spectinomycin
and adenylated spectinomycin products upon incubation with APH(9)-Ia and ANT(3",9),
respectively, have been identified using MALDI-MS. APH(9)-Ia induction studies in E.
coli tolC knock-out strains reveal a MIC increase against spectinomycin in the presence
of 2% arabinose compared to no shift with amSPCs. ANT (3")(9) showed an increase in
MIC against spectinomycin as well as amSPCs. In conclusion, amSPCs are not
inactivated by APH (9)-Ia in vivo but are inactivated by ANT (3")(9). Most Gramnegative bacteria isolated in clinics possess one or more AMEs. By overcoming
modification by AMEs, amSPCs can be a valuable tool in overcoming resistance in
Gram-negative bacterial infections. We also conducted a high throughput screen of a
polar small molecule library against two multi-drug resistant clinical isolates of
Escherichia coli that encode aminoglycoside modifying enzyme for small molecule
potentiators of amSPCs to yield 12 possible potentiating molecules that have been
confirmed by dose-response analysis.
Future work as a continuation of this project will involve further analysis of any
existing synergy between the potentiating molecules and amSPCs and target validation of
these potentiators.
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CHAPTER 1.

INTRODUCTION

Pre-antibiotic Era
The recorded history of infectious diseases caused by bacteria dates back to the
year 3000 BCE.[1] Bacterial infections have been the cause of the decline of mighty
empires and ancient civilizations in history. The plague of Athens in 430 BCE killed a
quarter of Athenian troops and spread to the people of Athens as troops returned after the
war. [1, 2] Research later revealed the original cause of the pandemic to be Salmonella
enteritica serovar typhi infection after the researchers at the University of Athens
sequenced the DNA from the teeth recovered from a mass grave.[2] The Justinian plague
caused by Yersinia pestis killed millions of people in the roman empire between 541 and
543. The Justinian plague is believed to have reduced three-quarters of the roman
population. [1-3] The second plague pandemic, the black death, in 1347 to 1351 killed 30%
of the people of Europe. There was no effective treatment of the plague apart from the
quarantine of infected people to contain the disease.[4, 5] The impact of bacterial disease in
both these instances was enormous due to the lack of knowledge of modern medicine and
no knowledge of antibiotics as we know it today.

Introduction of Antibiotics and Classes of Antibiotics
Science and modern medicine have progressed a lot since the above-described
instances, but even today, infectious diseases remain among the top contributors to death
globally.[6] An American biologist, Selman Waksman, defined 'antibiotics' as "chemicals
produced by a species of bacteria that antagonizes the growth of another bacterial
species." The term did not include synthetic antimicrobials not produced by
microorganisms.[7] Antibiotics were a unique class of therapeutic agents because they did
not target any human tissue; they targeted bacteria instead.[8] Dr. Waksman was
convinced that antibiotics had no role in influencing cellular processes in nature[9],
although now we have evidence that antibiotics play a role in nature at subinhibitory
concentrations.[10] The Discovery of Penicillin by Alexander Fleming, produced by the
mold Penicillium notatum in 1928, was a landmark in therapeutic medicine. It provided
modern medicine a critical tool to fight the infectious diseases caused by bacteria.[11]
There is evidence that antimicrobials were used long before introducing Penicillin in
some form, from the traces of tetracycline in human skeletal remains in Sudanese Nubia
in 350 AD, artemisinin in traditional Chinese medicine, and fluorochrome labeling of
tetracycline in ancient Egyptian skeletons.[12-15] Salvarsan was used to treat syphilis
infections even before introducing penicillin, but its chemical structure was unknown. It
had known toxicity in humans and the mode of action was not deciphered.[15] However,
the purification and mass production of penicillin and its introduction in clinics in the
early 1940s ushered the world into an antibiotic era.[11] Mrs. Annie Miller became the
first patient in the United States to be treated with penicillin for septicemia. She
recovered within hours.[16] Penicillin was successful in treating infections in soldiers
during world war II.[7] Antibiotics increased the life span by treating previously fatal
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diseases and played a vital role in advanced medical practices of implanting medical
devices and organ transplants.[17] Quite a few different classes of antibiotics like
sulfonamides and aminoglycosides that target other cellular processes of bacteria were
discovered after penicillin. The decades between 1940 - 1960 were the golden era of
antibiotic discovery.[18, 19]
An essential criterion for an antibiotic to be introduced in the clinic is its selective
toxicity to bacteria. Thus, it is imperative that they have well-defined targets in bacteria
while being non-toxic to the host infected by the bacterium against which they are
targeted. Different antibiotics disrupt various biochemical or physiological cellular
processes in bacteria, resulting in bacterial killing or cessation of growth and classified
based on their target cellular processes.[20] Antibiotics can be bacteriostatic and reversibly
inhibit bacterial growth; once the antibiotic is removed from the system, the bacteria can
continue to grow. Bactericidal antibiotics irreversibly cause bacterial cell death.[21]
Figure 1-1 summarizes the mechanism of action of various antibiotic classes. Based on
bacteria's cellular component targeted, antibacterials can be grouped into five broad
categories: Cell wall biosynthesis inhibitors, cell membrane disruptors, protein
biosynthesis inhibitors, metabolic pathway disruptors or antimetabolites, and nucleic
acid-targeting antibiotics.[22]
β-lactams disrupt the cell wall synthesis, which is also targeted by glycopeptides,
fosfomycin, and bacitracin.[22] Penems, clavams, carbapenems, cephems, oxacephems,
and monobactam halt peptidoglycan synthesis by inhibiting transpeptidase enzymes.
Peptidoglycan is vital to the integrity of the bacterial cell wall.[23] Glycopeptides disrupt
later stages of peptidoglycan synthesis by attaching to a pentapeptide precursor and
inhibiting the activity of transglycosylases and transpeptidases.[24] Fosfomycin interrupts
the early stages of peptidoglycan synthesis. It inhibits the activity of uridine diphosphate
(UDP)- N- acetylglucosamineenolpyruvyltransferase, an enzyme required to synthesize
UDP-N-acetylmuramic acid, a precursor required for peptidoglycan synthesis.[25]
Bacitracin interferes with the translocation of peptidoglycan precursors across the
bacterial membrane.[26]
Membrane-acting antibiotics include polymixins (natural polypeptides) and
lipopeptides like daptomycin.[21] Polymixins and colistins alter the membrane
permeability in bacteria.[27] Polymyxins do not inhibit Gram-positive bacterial growth
because they cannot penetrate the thick peptidoglycan layer. In Gram-negative bacteria
they can interact with negatively charged lipopolysaccharide. They insert a hydrophobic
moiety in the membrane by displacing the divalent cations disrupt it, thus, leading to
increased polymyxin uptake and disruption of the cell membrane.[28, 29] Lipopeptides are
amphiphilic and form micelle-like assemblies with calcium ions. These micelles cause
leakage of cellular contents and kill the bacteria.[30]
Protein synthesis disruptors bind to one of the ribosomal subunits and prevent
ribosomal translocation.[21] Tetracyclines and aminoglycosides attach to the 30S bacterial
ribosomal subunit. Aminoglycosides enter the Gram-negative bacteria by diffusion
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Figure 1-1.

Antibiotic classes and their mechanisms of action

Reprinted with permission from OpenStax Books. Nina Parker, M.S., Anh-Hue Thi Tu,
Philip Lister, Brian M. Forster Mechanisms of Antibacterial drugs, in Microbiology.
2016, OpenStax: Houston, Texas. Book Link:
(https://openstax.org/books/microbiology/pages/1-introduction) Section Link:
(https://openstax.org/books/microbiology/pages/1-introduction).
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through the membranes in an energy-independent manner. They inhibit the transfer of
peptide-carrying tRNA from Peptidyl-site to peptidyl T-RNA accepting site and inhibit
protein synthesis.[22] Tetracycline antibiotics diffuse through the membranes and interfere
with the initiation process by disrupting the attachment of nascent t-RNA to the Acceptor
site.[31] Macrolide, Lincosamides target the 50S subunit and block the peptide chain
elongation.[21, 32] Oxazolidinones prevent the formation of initiation complexes by
binding to the 50S ribosomal subunit.[22, 33]
Metabolic pathway targeting classes of antibiotics include folic acid synthesis
inhibitors like sulfonamides and trimethoprim. They are used in combination to treat
urinary infections. Sulfonamides inhibit the activity of dihydropteroate synthetase and
prevent tetrahydrofolic acid formation; trimethoprim competes with the substrate and
inhibits the dihydrofolate reductase enzyme.[34, 35] Isoniazid is used selectively to
Mycobacterial infection in combination with rifampin or streptomycin. It is administered
as a prodrug activated by bacterial peroxidases and interferes with mycolic acid
synthesis. Mycolic acid is the major component and vital for mycobacterial cell wall
synthesis.[21]
The nucleic acid-targeting antibacterials can inhibit DNA or RNA synthesis
inhibitors, including fluoroquinolones, nitrofurans, nitroimidazoles, and ansamycins. The
fluoroquinolones are semisynthetic analogs of nalidixic acid and enter the Gram-negative
bacterial cell via the porins in the outer membrane. They inhibit DNA topoisomerases,
enzymes involved in the supercoiling and uncoiling of DNA.[36] They form a tertiary
complex with DNA binding proteins and DNA itself.[22, 37, 38] The nitro group of the
nitroheterocyclic drugs undergoes enzymatic reduction to generate nitroso radicals.
Single-electron reductions can activate nitrofurans and enable them to inhibit enzymes
involved in glycolysis. Reduced nitrofurans can bind to DNA and enzymes.
Nitroimidazoles need complete reduction to be activated and are therefore only effective
against anaerobic and microaerophilic bacteria.[22, 39] Rifampin was the first major
semisynthetic ansamycin drug that selectively targeted the bacterial RNA polymerase. It
was used in combination with drugs like isoniazid to treat mycobacterial infections.
Rifabutin is a more recent successor of rifampin.[21, 40, 41]
These discoveries led to a belief in the medical community that the war against
infectious diseases was won. An Australian immunologist and virologist, Sir MacFarland
Burnett's stated, "by the end of the Second World War, it was possible to say that almost
all of the major practical problems of dealing with the infectious disease had been
solved." (Eccleston-Turner, M. and I. Brassington, Introduction, 2020, p.1)[42] Dr.
William H. Stewart, the surgeon general, claimed in 1971 that "it was time to close the
book on infectious diseases, declare the war against pestilence won, and shift national
resources to such chronic problems as cancer and heart disease."[19, 43] This euphoria was
short-lived, as the antibiotics started losing efficacy due to the rise in antibiotic-resistant
pathogens
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Antimicrobial Resistance
Resistance to antibiotics in bacteria can be described from two perspectives: one
from a population-based perspective where comparison is between the existing
population before exposure to antibiotics and the population surviving after exposure to
antibiotics. The second definition pertains to the adverse clinical outcome in an
uncontrolled infection after treatment with an antibiotic. European Committee on
Antibacterial Susceptibility Testing,[44], which releases breakpoint concentrations for
different antimicrobials annually, takes both these definitions into account.[45] Phenotypic
susceptibility testing methods for antimicrobials use either broth microdilution assay or
disk diffusion assay to calculate the drug's Minimum Inhibitory Concentration (MIC).
Both these assays test the bacterial growth inhibition ability of various concentrations of
a given antibacterial. The lowest concentration of antibiotics capable of inhibiting
bacterial growth is the MIC of the antibacterial being tested for the bacterium. Minimum
inhibitory concentration is different from minimum bactericidal concentration (MBC),
which explicitly indicates the concentration required to cause bacterial cell death;
inhibitory concentration indicates concentration needed to prevent bacterial cell growth
and multiplication.[45-47] According to the EUCAST definition, "A microorganism is
categorized as Resistant when there is a likelihood of therapeutic failure, even with
increased exposure" (Kahlmeter-EUCAST, 2019, p.17).[44] The EUCAST definition of
exposure is: "Exposure is a function of how the mode of administration, dose, dosing
interval, infusion time, as well as distribution, metabolism, and excretion of the
antimicrobial agent will influence the infecting organism at the site of infection."
(Kahlmeter-EUCAST, 2019, p.10)[44]
If the antibiotic MIC for a particular species of bacteria falls in the resistant range,
they are considered intrinsically resistant to the antibiotic. Bacteria can also acquire
resistant genes from closely or distantly related bacteria or mutate endogenous genes.[48,
49]
In the case of intrinsic resistance, bacteria may lack the antibiotic target, such as cell
walls lacking mycoplasmas, and exhibit inherent resistance to all cell wall targeting
antibiotics. Gram-negative bacteria exhibit intrinsic resistance to peptidoglycan targeting
antibiotics; they possess an outer membrane rich in lipopolysaccharide envelopes the thin
peptidoglycan layer.[49] They are also intrinsically resistant to quite a few current
antibiotics because of the difficulty in penetrating the lipopolysaccharide.[49, 50] An
excellent example of an intrinsically resistant bacterial species is Pseudomonas
aeruginosa; it has an inducible AmpC β- lactamase encoding gene and is resistant to
almost all β- lactams. They also possess a difficult to penetrate outer membrane and
multiple active efflux pumps that compromise fluoroquinolone activity, multiple
aminoglycosides, and cephalosporins.[49, 51] Acinetobacter spps are resistant to ampicillin
and glycopeptides. Anaerobic bacteria lack the mode of transport for aminoglycosides
and are therefore resistant to them.[48, 49]
Acquired resistance in bacteria may arise due to exposure to antibacterials or
mutation or acquired genetic changes. Bacteria can acquire resistance genes by all modes
of gene transfer or horizontal gene transfer, including transformation, transposition, and
conjugation. The most common method of resistance acquisition is the plasmid-mediated
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transmission, though transposons and insertion sequences have an essential part in the
internal movement of genetic material.[48, 49, 52, 53] External mutagens like UV radiation
and chemical mutagens can cause mutations in the antibiotic target genes and give rise to
resistant mutations.[54] Subjection to sublethal antibiotic concentrations leads to the
selection of a bacteria highly resistant with increased mutation rates.[55]
The Antibiotic Paradox, a book by Dr. Stuart Levy, discusses the effects of
unrestrained antibiotic use as prophylactics on animal farms and unwarranted use in
humans. In brief, prescribing broad-spectrum antibiotics at the beginning of infection by
clinicians, access to antibiotics without the need of a prescription, improper dosing of
antibiotics can all lead to a rise in antimicrobial resistance.[48, 56] The spread of resistance
has also been attributed to the indiscriminate utilization of antibiotics in the animal
rearing industry, leading to the accumulation of meat and effluents of these animal farms
and contamination of the irrigation sources for crop farming. Similarly, human waste
contaminating water sources also contributes to the spread.[57] Attributing the increased
rates of resistance exclusively to overuse of antibiotics in humans and animals may not be
accurate; rise in resistance due to overuse holds for clonal dissemination of pathogenic or
disease-causing bacteria with resistance imparting mutations or positive selection of
mutations. However, it has been observed that horizontal gene transfer between
taxonomically and ecologically distantly related bacteria also contributes to antimicrobial
resistance.[58] A study conducted by Datta and Hughes in 1983 concluded that conjugative
plasmids that imparted antibiotic resistance were not spreading in response to antibiotic
use but instead could be attributed to the inclusion of resistance genes in the pre-existing
plasmids.[59] The resistance genes have existed for millions of years in the environment,
as suggested by studying a cave bacterium Paenibacillus spLC231 isolated from the
underground Lechuguilla cave ecosystem isolated from the surface ecosystem for four
million years. This study traced the origin of existing resistance genes and identified a
few new ones that have not been seen in clinics yet. If these elements are mobilized into
pathogenic bacteria, they can raise serious concerns in the treatment strategies for
resistant bacterial infections.[60]
Resistance to penicillin was observed not long after its introduction, and there is
evidence that Penicillin-resistant Staphylococcus was identified in 1940, even before it
was commercially available for public use.[61] By 1960 the resistance to Penicillin spread
enough to reach pandemic proportions, introducing semisynthetic penicillins like
methicillin. Within a year of its introduction of methicillin, resistance was reported in the
UK [9] and the USA in 1968.[7, 62] A timeline of discovery and resistance development to
antimicrobials from CDC and Figure 1-2 suggests that resistance to antimicrobials in
microbes is as old as antibiotics.[63] A continued rise in antibiotic resistance has left
clinicians with fewer treatment strategies and rising mortality due to infections, which
imposes a tremendous burden on our society in terms of total death and loss of gross
domestic product.[64]
According to the 2019 CDC Antibiotic Resistance report, drug-resistant
microbes(bacteria and fungi) cause about 3 million infections and 35000 deaths in the
United States alone. The CDC also estimated the economic impact of antimicrobial
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Figure 1-2.

Timeline of discovery of antibiotics and resistance observed

Reprinted with permission from the Royal Society of Chemistry. Hall, T.J., et al., A call
for action to the biomaterial community to tackle antimicrobial resistance. Biomaterials
Science, 2020. 8(18): p. 4951-4974. DOI: 10.1039/D0BM01160F.

7

resistance due to fatalities and loss of productivity to be 35 billion USD per year. The
CDC report lists Carbapenem-resistant Acinetobacter and Enterobacteriaceae under
urgent threats along with Clostridium difficile and Neisseria gonorrhea. There are ten
drug-resistant bacteria on the serious threats list.[63] A continued rise in antibiotic
resistance has left clinicians with fewer treatment strategies and rising mortality due to
infections, which imposes a tremendous burden on our society in terms of total death and
loss of gross domestic product.[64] A 2014 review on antimicrobial resistance by the
United Kingdom government estimates that, if left unchecked, antimicrobial resistance
can cause ten million deaths per year globally, and the economic cost can be up to 100
trillion US dollars.[65] In the World Health Organization fact sheet on antimicrobial
resistance released in October 2020, the rate of ciprofloxacin resistance in Escherichia
coli was 8.4% to 92.9% and for Klebsiella pneumoniae between 4.1% to 79.4%.
Ciprofloxacin is used in urinary tract infection treatment. These numbers are just from 25
countries that participate in GLASS. GLASS stands for Global Antimicrobial Resistance
and Use Surveillance System. This report also states that the clinical pipeline for new
antimicrobial has run dry; only 6 out of 32 antibiotics WHO identified as relevant to its
priority pathogens list were innovative

Resistant versus Persistent Bacteria
Antibiotic-resistant bacteria should not be confused with persister bacterial cells,
which form about one percent of bacterial culture in the stationary phase. Persister
bacterial cells do not grow and do not die in the presence of antibiotics and thus lead to
antibiotic tolerant populations like those found in biofilms. Failure of antibiotics to treat
an infection can be due to resistance, but tolerance and persistence may also contribute to
this failure. By slowing down essential bacterial processes, tolerant bacterial populations
can survive antibiotic pressure without modifying minimum inhibitory concentration
(MIC).[66, 67] Persister cells are metabolically inactive due to a state of dormancy and can
be tolerant to higher antibiotic concentrations with no genetic changes.[68, 69] ToxinAntitoxin loci of prokaryotes comprise a 'toxin' that is generally stable and an 'antitoxin,'
which can be an unstable protein or RNA that can neutralize the toxin. TA loci types I
and II encode RNA toxins that regulate toxins by controlling their translation by
antisense RNA or by interfering with post-translational modifications by directly binding
to toxins.[70] Involvement of Type II Toxin-Antitoxin loci in persistent cell formation is
supported by evidence of TA mRNA transcript upregulation seen in the persister fraction
of a hipA7 mutant.[66, 71-73] Research of persister formation in Escherichia coli, E. cloacae,
and Staphylococcus aureus provide insights into environmental factors that can activate
stringent response that results in persister formation. In E. coli, the stringent response
pathway can switch bacterial metabolism from rapidly growing to slow-growing by
altering the response of about 500 genes.[74] ppGpp binds directly to RNA polymerase
and inhibits tRNA and rRNA promoters. This leads to the accumulation of RpoS, which
regulates the stress response in the stationary phase.[75] Deleting relA and spoT causes a
drop in persister cell formation in Escherichia coli.[74, 76] They encode for ppGpp
synthetases, respectively.[77] A proposed model of the ppGpp network in E. coli is based
on observing differences in ppGpp levels when grown in a medium with different carbon
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sources. During the transition from glucose utilization as the carbon source to a
secondary sugar, the cells exhibited a switch to the stringent response, and ppGpp levels
increased. In this study, the increased ppGpp results in reduced DNA supercoiling,
indicating inhibition of DNA gyrase. Drug tolerant cells of Pseudomonas aeruginosa and
E.coli that grow in biofilms' nutrient-restricted environment also require ppGpp.[74, 78, 79]

Mechanisms of Resistance in Bacteria
Mechanisms for resistance to antibacterials can be divided into four groups: 1:
restricted or limited uptake, 2: Active drug efflux systems, 3: Target site modification,
and 4: Drug inactivation. Figure 1-3, a cartoon of the resistance mechanisms, briefly
explains the four resistance mechanisms. Innate or intrinsic resistance can involve
limited uptake, efflux, and drug inactivation mechanisms, whereas acquired resistance
includes target modification and activating efflux. Gram-positive and negative bacteria
utilize different mechanisms to develop resistance to antibiotics. Gram-positive bacteria
stain violet in Gram's staining protocol are rich in peptidoglycan but lack the
lipopolysaccharide outer membrane and have fewer efflux pumps. Antibiotics have better
access to Gram-positive bacterial cells. Gram-negative bacteria are stained pink in Gram's
staining protocol and have the lipopolysaccharide membrane that can utilize all the
resistance mechanisms and hence cause infections more challenging to treat.[48, 80]

Limited or Decreased Uptake
Gram-negative bacteria benefit the most from this mechanism as they possess an
outer membrane. The impermeability of the outer membrane is owed to its asymmetric
nature. The leaflet facing the periplasmic space comprises phospholipids, and the outer
leaflet is formed by lipid A tails. Antibacterials cross the outer membrane via Porins that
include trans-membrane channels or self- uptake.[81] The image of the Gram-negative cell
wall in Figure1-4 by Manchester et al. explains the complexity of the outer membrane
and the placement of Porins and their association with efflux pumps. The lipid A tails that
extend from the outer membrane prevent most antibiotics from crossing the outer
membrane except small polar molecules that pass through the porins.[82] Antibiotics of
the class β- lactams and fluoroquinolones enter the Gram-negative bacterial cells through
porins.[83, 84] Mutations in the lipopolysaccharide of P. aeruginosa and V. cholerae are
known to render them hyper susceptible.[85, 86] Gram-positive bacteria lack an outer
membrane. Still, vancomycin -resistant S. aureus undergoes an unexplained mechanism
that enables it to produce a thickened cell wall that reduces the efficacy of vancomycin in
killing them.[87]
Polar antibiotics like aminoglycosides have difficulty penetrating the cell walls of
Enterococci; thus, enterococci are intrinsically resistant to aminoglycosides.[88]
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Figure 1-3. Mechanisms of resistance: target modification, increased efflux,
decreased or limited uptake, and drug modification or inactivation

Figure 1-4. The Gram-negative cell envelope showing the lipid A tails of
lipopolysaccharide that emanate out of the outer membrane and the porins
placement
Reprinted with permission from Manchester, J.I., et al., Molecular Determinants of
AcrB-Mediated Bacterial Efflux Implications for Drug Discovery. Journal of Medicinal
Chemistry, 2012. 55(6): p. 2532-2537. Copyright {2012} American Chemical Society.
DOI: 10.1021/jm201275d.
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Active Drug Efflux Systems
Efflux pumps can be constitutively expressed or can be induced or overexpressed
upon receiving environmental cues.[48] Bacterial multidrug efflux systems can pump out
structurally unrelated chemicals and antibiotics utilizing the energy generated by ATP
hydrolysis. Drug efflux pumps form about six to eighteen percent of all transporters in
the bacterial cell.[81, 89] The five families of bacterial efflux systems are summarized in
Figure 1-5.[81]
Efflux pumps are also classified into one component or multicomponent systems.
RND family are multicomponent efflux systems explicitly found in Gram-negative
bacteria. They span from the outer membrane to periplasm to the cytoplasmic membrane
and catalyze efflux via the substrate-proton antiport mechanism; they pump out the
cytoplasmic substrate by working in tandem with membrane-fused and outer membrane
proteins.[81, 90, 91] AcrAB-TolC from Escherichia coli is the most studied RND family
efflux pump; it confers resistance to penicillin, fluoroquinolone, chloramphenicol.
Another RND efflux pump is the MexAB-OprM from Pseudomonas aeruginosa; it
confers resistance to all antibiotic classes as the AcrAB-TolC and sulfa-drugs.[48, 81, 90-92]
MacB of the ABC superfamily and EmrB of the MFS- Major Facilitator
Superfamily work with TolC as tripartite pumps to efflux macrolides nalidixic acid.[93, 94]
The MATE and MFS families exist in Gram-positive bacteria and can impart intrinsic
resistance to them. NorA efflux pump from Enterococcus faecalis and Staphylococcus
aureus belongs to the MFS family and catalyzes substrate efflux via the substrate-proton
antiport or solute/cation symport mechanism. It imparts resistance to fluoroquinolones
and chloramphenicol.[81, 90, 95, 96] NorM efflux pump from Neisseria gonorrheae belongs
to the MATE family and uses the energy from Na+ gradient and helps efflux cationic
dyes and most fluoroquinolones.[97, 98]
ABC or ATP binding cassette family pumps are made of six transmembrane
helices that function as pairs of homo or heterodimers combined with ATPases. These
efflux pumps are rare in bacteria. This family has both uptake and efflux transport
systems and derives energy from ATP hydrolysis. An example is VcaM from Vibrio
cholerae and imparts resistance to fluoroquinolones and tetracycline and LmrA from
Lactococcus lactis.[81, 99, 100]
SMR family efflux pumps transport lipophilic cations. They can transport a
narrow range of substrates and utilize energy generated by the proton motive force. Very
few of these pumps confer resistance to antibiotics, but EmrE from Escherichia coli
impart resistance to β- lactams and erythromycin and tetracycline.[81, 90]

Target Site Modification
Antibiotics target different cellular components in bacteria, and these targets can undergo
modification to evade antibiotic action. One such example is the PBP-2a, a
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Figure 1-5.

Types of efflux systems in bacteria

Reprinted with permission from Elsevier. Kumar, A. and H.P. Schweizer, Bacterial
resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev, 2005.
57(10): p. 1486-513. DOI: 10.1016/j.addr.2005.04.004.
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protein that binds to penicillin, of Staphylococcus aureus that undergoes a structural
change by acquiring the mecA gene to prevent the binding of β- lactams.[101] Another
example is the methylation of ribosomal subunits by acquiring erm genes to prevent
aminoglycoside or macrolide, modification of streptogramins binding site, and ribosomal
protection to prevent tetracycline binding to bacterial ribosomes.[102, 103] Changes in the
structure of DNA gyrase due to mutations in the gyrA gene and grlA in case of Gramnegative and positive respectively impart fluoroquinolone resistance, which targets
nucleic acid synthesis in bacteria.[104, 105] Sulfonamides target the enzymes
dihydropteroate synthase in the folic acid synthesis pathway; mutations near the active
site of these enzymes prevent the drug binding and thus confer resistance.[106, 107]

Drug Inactivation
Enzymatic modification of drugs has been the most relevant resistance
mechanism since the discovery of Penicillin and its hydrolyzing enzyme penicillinase.[108]
Antibiotics can be either modified by adding chemical groups or cleaved by bacterial
enzymes to render them inactive. One mode of resistance is hydrolyzation by βlactamase enzymes. Another drug that is subjected to hydrolyzation is tetracycline via the
TetX enzyme.[102, 109] The β- lactamases cause the β- lactam ring to cleave in a specific
site and losing activity by preventing binding to penicillin-binding proteins (PBPs). βlactamase production is a critical intrinsic resistance mechanism against β- lactams,
especially in Gram-negative bacteria. The four kinds of β- lactamases: A, B, C, and D are
classified based on molecular structural variations. They can be classified based on their
functional groups into the serine β-lactamases, the cephalosporinases, and the metallo(zinc-dependent) β-lactamases based on their substrate specificities.[102, 110-112] βlactamases can be either chromosomally encoded in Gram-negative bacteria or on
plasmids in some cases like Enterobacteriaceae. In Gram-positive bacteria like
Enterococcus facium, Enterococcus faecalis, and Staphylococcus aureus, they are
encoded in plasmids.[112, 113] There has been a recent surge in β-lactamases that inactivate
carbapenems and are called carbapenemases. The two most notable are carbapenemases
found in Klebsiella pneumoniae (KPCs), a serine class A β-lactamase, and Carbapenemresistant Enterobacteriaceae resistant enzymes metallo- β-lactamases class B.[108, 110, 114,
115]
Current emphasis is on finding the right β-lactamases inhibitor combination that can
inhibit carbapenem-resistant Enterobacteriaceae enzymes; an example of this is
ceftolozane/tazobactam pair, active against Pseudomonas aeruginosa infections and a
few ESBL producing Gram-negative bacteria.[116, 117]
Aminoglycoside modifying enzymes (AMEs) form a significant part of acquired
aminoglycoside resistance. They can be classified into three major classes:
Adenyltransferases (ANT), Phosphotransferase (APH), and Acetyltransferase (AAC)
based on the functional group attached to the drug they catalyze.[118] AMEs catalyze the
acetylation, adenylation, or phosphorylation of amino or hydroxyl groups of the 2deoxystreptamine nucleus of multiple related aminoglycosides.[119] The spectrum of
resistance of these enzymes depends on the specificity of the enzymes. Some AMEs can
modify multiple substrates; for example, ANT(3")(9) can adenylate streptomycin or
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spectinomycin. Some AMEs can only modify one substrate or aminoglycoside like
APH(9) -Ia from Legionella pneumophila that phosphorylates spectinomycin alone.
AMEs inactivate the aminoglycosides before they bind to the ribosomes and can be
acquired or chromosomally encoded. AACs, catalyze the transfer of the acetyl group to
the amino groups of aminoglycosides from acetyl Co. A. They can catalyze acetylation of
positions 1, 3, 2'and 6' and are named based on positions they catalyze the acetylation at.
These groups are divided further into subclasses and spread across multiple genus and
species of bacteria. ANTs catalyze adenylation of aminoglycosides using adenosine -5’triphosphate. They are divided into groups based on the positions they catalyze the
adenylation. APHs phosphorylate the hydroxyl group using adenosine -5’-triphosphate as
the phosphate group donor. They are divided into classes and further into subclasses
based on the position being phosphorylated. There are also bifunctional AMEs that
acetylate as well as phosphorylate or acetylate as well adenylate. One such example is
AAC(6′)-APH(2′′) enzyme from Staphylococcus aureus and Enterococcus faecalis.[118,
120-123]
In the next chapter, we discuss the aminoglycoside modifying enzymes in detail.
Now that we have introduced the mechanisms of resistance that exist in bacteria,
in the following two chapters, we discuss in more detail the mechanisms of resistance
that spectinomycin and its analogs-aminomethyl spectinomycins (amSPCs) are subjected
to in Gram-negative bacteria and the strategies to overcome the bacterial resistance
mechanisms.
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CHAPTER 2. CHARACTERIZING THE SUSCEPTIBILITY OF SECONDGENERATION AMINOMETHYL SPECTINOMYCINS TO
AMINOGLYCOSIDE MODIFYING ENZYMES

Introduction
Antibiotic-resistant infections are becoming increasingly common. According to a
CDC report on antimicrobial resistance in 2019, approximately 2.9 million people in the
United States alone get sick due to antibiotic-resistant infections.[124] The World Health
Organization fact sheet released in October 2020 states that the clinical pipeline for new
antimicrobial has run dry, and only 6 out of 32 antibiotics identified as relevant to the
priority pathogens list were innovative.[125] The declining rate of discovery of new
antibiotics can be attributed to the long timelines associated with discovering new
chemical matter and validation of the target of any novel antibacterial.[126] One way of
addressing the rising antibiotic resistance is the chemical modification of the existing
natural product or their derivatives to overcome the known resistance mechanism in
bacteria.[127, 128] Adopting this strategy, we revisited spectinomycin, which belongs to the
aminocyclitol group of antibiotics; this group includes aminoglycosides.[129]
Spectinomycin interrupts protein synthesis in bacteria by sterically hindering the
movement of the 30S subunit of ribosomal RNA and thus blocking translocation.[130, 131]
Researchers at Upjohn Company first modified spectinomycin; Trospectinomycin
reached late-stage clinical trials and was more potent against Enterobacteriaceae and
Chlamydia trachomatis as compared to spectinomycin. Its development was stopped for
commercial reasons in favor of cephalosporins and second-generation macrolides.[132]
Upjohn Company first identified the aminomethyl spectinomycin scaffold in the 1980s
and made N-benzyl substitutions to the aminomethyl side chain to synthesize
aminomethyl spectinomycin with the help of structure-based design methods.[133, 134] The
first-generation aminomethyl spectinomycins (amSPC) effectively inhibited the growth
of respiratory tract pathogens like Streptococcus pneumoniae and sexually transmitted
pathogens like Neisseria gonorrheae and Chlamydia trachomatis.[133] In vivo efficacy of
lead amSPC, 1950 in clearing complex upper respiratory tract infections and middle ear
infections in mice has also been established.[135] Brunh et al. checked the inhibitory
activity of amSPCs against a panel of respiratory tract pathogens and noted that amSPC's
were inhibiting the growth of Legionella pneumophila, whereas spectinomycin did not
inhibit growth. Legionella pneumophila is a Gram-negative respiratory tract pathogen
that encodes an aminoglycoside modifying enzyme APH(9)-Ia.[133, 136]
We are now checking the susceptibility of second-generation amSPCs- see Figure
2-1 to the aminoglycoside modifying enzymes. APH(9)-Ia specifically phosphorylates the
hydroxyl group on the 9th carbon of spectinomycin. The aph gene chromosomally
encodes it in Legionella pneumophila.[137, 138] This observation led us to hypothesize that
amSPCs were not modified by the aminoglycoside modifying enzymes that inactivate
spectinomycin and impart resistance to bacteria encoding them. The most common
resistance mechanism seen in bacteria against aminoglycoside antibiotics is
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Figure 2-1. Structures of spectinomycin and second-generation aminomethyl
spectinomycin lead amSPC2593
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aminoglycoside modifying enzymes (AMEs).[139] Antibiotic-resistant infections are
becoming increasingly common. According to a CDC report on antimicrobial resistance
in 2019, approximately 2.9 million people in the United States alone get sick due to
antibiotic-resistant infections.[124] The World Health Organization fact sheet released in
October 2020 states that the clinical pipeline for new antimicrobial has run dry, and only
6 out of 32 antibiotics identified as relevant to the priority pathogens list were
innovative.[125] The declining rate of discovery of new antibiotics can be attributed to the
long timelines associated with discovering new chemical matter and validation of the
target of any novel antibacterial.[126] One way of addressing the rising antibiotic
resistance is the chemical modification of the existing natural product or their derivatives
to overcome the known resistance mechanism in bacteria.[127, 128] Adopting this strategy,
we revisited spectinomycin, which belongs to the aminocyclitol group of antibiotics; this
group includes aminoglycosides.[129]
Spectinomycin, structurally similar to aminoglycosides, is subjected to
modification by phosphotransferases and Adenyltransferases (see Figure 2-2). The
nomenclature of these enzymes is complex and confusing; there are two formats of
nomenclatures generally used. One format uses the three-letter identifier that describes
the activity followed by a number in parenthesis indicating the position of the substrate
being modified, followed by a hyphen and a roman number unique to the resistance
profile of the bacteria, and a lower-case alphabet which is a unique identifier. The other
format uses the lower case three-letter gene name activity indicator followed by an uppercase letter A, B, or C indicating positions of aminoglycoside being modified followed by
a number that serves as a unique identifier.[118, 140-142] APHs, phosphorylate hydroxyl
groups on aminoglycosides in a metal-ATP dependent manner, the metal being
magnesium. APH(9)-is divided into APH (9)-Ia, produced by Legionella pneumophila as
mentioned earlier, and APH(9)-Ib, produced by Streptomyces flavopersicus. APH(9)-Ia
and APH(9)-Ib have no significant homology, rather APH(9)-Ia has structural similarities
to the folding of APH(3′) and APH(2″) enzymes.[136] We cloned the APH(9)-Ia and a
dual-specificity adenylating enzyme ANT(3")(9) or aadA that adenylates spectinomycin
and streptomycin from a clinical isolate of Escherichia coli. ANT(3")(9) enzymes are
very widely distributed in Gram-negative as well as Gram-positive bacteria, as shown in
Table 2-1. We checked the distribution of the aadA gene in the CARD database and
learned that multiple genes encode for the same enzymes (aadA1-aadA13 and many
more).[143] The kinetic and mechanism of action analysis for both the enzymes has
revealed that both the enzymes bind to ATP and magnesium first and then bind to
spectinomycin.[137, 144] APH(9)-Ia changes conformation upon ATP binding and then
binds spectinomycin.[137] ANT(3")(9) adenylates the hydroxyl groups on 3" carbon of
streptomycin and 9th carbon of spectinomycin and hence the name ANT(3")(9). The
different ANT enzymes have low sequence identity matches but share a common fold for
ATP and magnesium binding.[145]. Mechanism of action and crystal structures of a few
bifunctional and dual-specificity ANT enzymes have been elucidated, and these include
ANT(3")(9) from Salmonella enterica (Uniprot ID Q8ZPX9), ANT(3")(6) from Serratia
marcescens (Uniprot ID Q8VQN7) and a spectinomycin only adenylate ANT(9) from
Enterococcus faecalis (Uniprot ID Q07448).
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Figure 2-2.

Spectinomycin site modified by aminoglycoside modifying enzymes
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Table 2-1.
Distribution of ANT(3")(9) or aadA gene in chromosomes or plasmid
of bacterial species as reported in NCBI
Species with aadA Gene
Acinetobacter baumannii
Citrobacter freundii
Enterobacter cloacae
Enterobacter hormaechei
Escherichia coli
Klebsiella aerogenes
Klebsiella pneumoniae

NCBI
NCBI
Chromosome % Plasmid%
38.04
0.47
13.16
6.60
9.30
6.90
3.23
7.14
1.71
1.51
0.00
6.00
0.40
2.25

NCBI
WGS %
31.39
17.20
14.06
23.35
13.01
5.63
15.49

Morgan morganii
Mycobacterium tuberculosis
Proteus mirabilis
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Pseudomonas putida

29.41
0.00
33.33
25.00
37.5
20.0
3.07
0.00

0.00
0.00
5.56
0.00
0.00
5.88
1.92
10.0

12.50
0.02
49.16
20.00
21.88
12.5
1.70
1.04

Raoultella planticola
Salmonella enterica

0.00
1.39

5.88
4.32

10.71
5.46

Serratia marcescens
Shigella dysenteriae
Shigella flexneri

3.23
8.33
54.17

3.41
5.88
0.00

13.11
35.29
83.06
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In this study, we are checking the ability of the phosphorylating enzyme [Aph(9)Ia] and adenylating enzyme [ANT(3")(9)] to modify spectinomycin analogs in Gramnegative bacteria. We have designed and used a MALDI mass spectrometry-based
enzymatic assay to detect phosphorylated or adenylated spectinomycin or amSPC end
products. This assay will also enable us to identify inhibitors of aminoglycoside
modifying enzymes APH(9)-Ia and ANT(3")(9). We have also solved the crystal
structure of the ANT(3")(9) from Escherichia coli bound to substrate spectinomycin with
non-hydrolyzable ATP analogs and with the adenylated spectinomycin product to help us
understand critical interactions to help us design inhibitors of these enzymes.

Materials and Methods
Expression in E.coliΔtolC and Arabinose Induction Minimum Inhibitory
Concentration
Arabinose inducible pBAD plasmid constructs with aph gene from Legionella
pneumophila and aadA13 gene with Ampicillin resistant markers were ordered from
Genscript. These were transformed into chemically competent E.coli BL21(DE3) cells.
These cells were plated on ampicillin containing Luria Bertoni (LB) agar plates to check
for successful transformation and later grown in LB broth to mid-log; the plasmids were
extracted using QIAGEN mini-prep kit and then electroporated into E.coliJW25113ΔtolC
cells ordered from the Keio collection. These APH(9)-Ia and ANT(3")(9) expressing
E.coliΔtolC cells were then used in broth microdilution assay to determine the minimum
inhibitory concentration of spectinomycin, streptomycin, and amSPC analogs as
described by Guzman et al.[146] Briefly, E.coliJW25113ΔtolC expressing both the
enzymes were grown in LB broth containing ampicillin to mid-log and then diluted to an
OD of 0.001 in cation adjusted Mueller Hinton broth containing 2% Arabinose for
induction of the enzymes. These were then added to 96-well plates containing the drug or
test compound 1;2 serial dilutions in Mueller Hinton broth, with the highest
concentration being 400 µg/mL. The plates were incubated at 370C with 5% CO2 for 1618 hours and then scanned on a document scanner to check for growth inhibition.

Overexpression and Purification of APH(9)-Ia and ANT(3")(9)
pET21b plasmid constructs with aph gene from Legionella pneumophila and
aadA13 gene with ampicillin-resistant markers were ordered from Genscript. These were
transformed into chemically competent E.coli BL21(DE3) cells. These cells were plated
on ampicillin containing Luria Bertoni (LB) agar plates to check for successful
transformation. Single colonies were inoculated in 10mL of LB broth and grown to midlog; glycerol stocks of the mid-log were made and at -800C. For scaleup induction and
expression of each enzyme, 10 mL starter cultures from glycerol stocks were inoculated
and grown overnight while maintaining the ampicillin 100mg/mL concentration. The
starters cultures were then added to 2L LB broth and grown to mid-log at 370C, aph gene
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was induced with 0.5 mM of IPTG, and the culture was then incubated at 200C for 8
hours, and then the cells were harvested. The purification protocol was modified from
Lemke et al.[156] aadA13 gene was induced with 1mM IPTG at mid-log and then
incubated at 160C overnight before the cells were harvested by centrifuging at 3500 G for
15 minutes. The supernatant was then discarded, and the cell pellet was stored at -200C.
For purification, the frozen pellets were thawed and resuspended in 50 mM Tris HCl and
150 mM Sodium chloride and 30mM Imidazole-containing lysis buffer of pH 8
containing 0.2g of lysozyme and two protease inhibitor pellets. This suspension was then
sonicated and centrifuged at 14000 rpm for 30 minutes to separate the cell debris from
the protein-containing supernatant. This supernatant was passed through a 0.22-micron
filter. This filtrate was loaded onto a 5mL capacity nickel affinity column using AKTA
pure FPLC system; the column was washed with 5X column volume of the loading buffer
and protein eluted with an increasing imidazole gradient. The fractions showing the
protein peak on the chromatogram were collected and run on a 10% polyacrylamide gel.
The fractions with the right size protein band were pooled and further purified using size
exclusion columns into a 50mM Hepes, 150mM Sodium chloride, and 1mM DTT buffer
and stored with 10% glycerol at -800C.

Agar-Based Enzyme Activity Assay
As described previously, Luria Bertoni agar plates containing 100mg/mL of
spectinomycin, streptomycin, or amSPC analogs were prepared and plated with a mid-log
culture of non-transformed E.coli BL21 cells sensitive to the test compound. 50 µM of
purified protein with 5 mM ATP in a buffer with 50mM Hepes, 150mM Sodium
Chloride, and 10mM of MgCl2 at pH 7.5 was spotted on a Whatmann filter paper disc
placed in the center of the agar plate and incubated at 370C overnight, and growth around
the disc was visually checked for after the overnight incubation. The protocol was
adapted and modified from Carter and Sykes.[148]

MALDI- Mass Spectrometry-Based Enzyme Assay
We first optimized the signal for chemically synthesized phosphorylated
spectinomycin with a mass of 413.13 Da, shown in Figure 5. The enzymatic reactions for
APH(9)-Ia were modified from Thompson et al. and Wright et al.[136, 157] Briefly, the
reaction was initiated by adding APH(9)-Ia spectinomycin and amSPC analogs in 50 mM
Hepes buffer (pH 7.5) containing 150 mM Sodium chloride and 10 mM MgCl2. The
reaction was incubated at room temperature and quenched after 20 minutes with 1%
Trifluoroacetic acid (TFA). MALDI matrix 2,5-Dihydroxybenzoic acid (DHB) was
dissolved at 20 mg/mL in 1% TFA and 30% Acetonitrile. The quenched reaction was
mixed with DHB in a 1:10 ratio and spotted onto a 384-well Big Anchor MTP target.
Substrate (spectinomycin, 333.1 Da) and product (phosphorylated spectinomycin, 413.1
Da) were detected on a 7 T Solarix XR (FT-ICR) mass spectrometry (Bruker Co, MA,
USA) in positive ionization mode. The laser power was adjusted to 22%, 600 laser shots
with a frequency of 200 Hz. Multi-casi settings were Q1 mass of 333.1 for substrate and
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413.1 for product, isolation window was set to 1.0, collision voltage was -4.00, and signal
to noise threshold was 3.0. Ion intensity of substrate and product was used to calculate
the % Turnover using Equation 2-1:

% Turnover = (𝐼

𝐼𝑃
𝑃 +𝐼𝑆

) × 100

(Eq. 2-1)

Where Ip is the product ion intensity and IS is the substrate ion intensity.
Data was processed using Compass DataAnalysis software (Bruker Co, MA,
USA), the R package Tidyverse,[158-160], and GraphPad Prism.[161] The Michaelis-Menten
equation in the GraphPad Prism is listed in Equation 2-2.
𝑌 = 𝑉𝑚𝑎𝑥 ∗ 𝑋/(𝐾𝑚 + 𝑋)

(Eq. 2-2)

Enzyme gradients were run from 20 nM to 50 µM to check the extent of
phosphorylation of amSPCs compared to spectinomycin at different enzyme
concentrations. The concentration of spectinomycin or amSPC was kept constant at 300
µM, and ATP was constant at 1mM. The reaction was carried out at room temperature
and quenched at 20 minutes.
Km was calculated using varied substrate concentrations from [10 µM to 60 µM
with 5 µM increments] with the enzyme concentration held constant at 100 nM and ATP
at 1 mM with data collected at multiple time points from 30 seconds to 20 minutes.
The chemical synthesis of adenylated spectinomycin was complex, so we biochemically
synthesized it by incubating spectinomycin with purified ANT(3")(9).[144] ANT(3")(9)
was carried out as previously described by Kim et al. and Green et al.[144, 162] The
adenylated product was then purified, and the 680.22 Da was detected on a 7 T Solarix
XR Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry (Bruker
Co, MA, USA) in positive ionization mode, as shown in Figure 5. Briefly, the reaction
was initiated by adding ANT(3")(9) and spectinomycin in 50 mM Hepes buffer (pH 7.5)
containing 150 mM Sodium chloride and 10 mM MgCl2. The reaction was incubated at
room temperature and quenched after 20 minutes with 0.1% Trifluoroacetic acid (TFA).
MALDI matrix 2,5-Dihydroxybenzoic acid (DHB) was dissolved at 20 mg/mL in 1%
Formic acid and 95% Methanol. The quenched reaction was mixed with DHB in a 1:10
ratio and spotted onto a 384-well Big Anchor MTP target. Substrate (spectinomycin,
333.1 Da) and product (adenylated spectinomycin hydrate, 680.22 Da) were detected on a
7 T Solarix XR Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass
spectrometry (Bruker Co, MA, USA) in positive ionization mode. The laser power was
adjusted to 22%, 200 laser shots with a frequency of 800 Hz. Multi-casi settings were Q1
mass of 333.1 for substrate and 680.22 for product, isolation window was set to 10,
collision voltage was -4.00, and signal to noise threshold was 3.0. The Michaelis-Menten
constant (Km) was calculated using varied substrate concentrations from [2.5µM to 160
µM with 1:2 serial dilution] with the enzyme concentration held constant at 100 nM and
ATP at 1 mM with data collected at multiple time points from 30 seconds to 60 minutes.
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ANT(3")(9) Sequence Alignment and Crystal Growth
Sequence alignment of Escherichia coli, aadA13 encoded ANT(3")(9) and
ANT(3")(9) from other bacterial species was performed using NCBI BLAST tool, and
output figure acquired using the COBALT- (constraint-based sequence alignment tool)
sequence alignment tool.[154, 155]
ANT(3")(9) was co-crystallized with AMP-PNP and spectinomycin using
hanging drop vaporization methods. Equal volumes of the purified ANT(3")(9) at
20mg/mL were incubated with 5mM AMP-PNP, 5mM spectinomycin, and 5mM
magnesium chloride overnight at 40C. Equal volumes of the protein mix were mixed with
an optimized crystallization solution containing 0.1M MES pH 6.2, 0.1M NH4Cl, and
15% PEG 6,000. When grown at room temperature, crystals typically appeared within 14
days. Crystals were harvested in a cryoprotective solution containing 0.1M MES pH 6.2,
0.1M NH4Cl and 15% PEG 6,000, and 25% glycerol and stored in liquid nitrogen.

ANT(3")(9) AMP-PNP and Spectinomycin Data Collection and Refinement
A high-resolution data set of ANT(3")(9) co-crystallized with AMP-PNP and
spectinomycin were collected to 1.26Å at the Advanced Light Source (ALS) at the
Lawrence Berkeley National laboratory beamline 502 by St Jude X-ray Crystallography
staff. Data were indexed and scaled by X-ray photoelectron spectroscopy (XPS) in space
group P212121 to a final resolution of 1.76Å. Molecular replacement solutions were
identified using Phaser with a starting Protein Data Bank (PDB) model: 4CS6, which was
prepared using a Sculptor to remove all non-identical side-chain atoms. The structure was
refined using PHENIX and Coot until an acceptable Rfree and Rwork were achieved.
Figures were made using Pymol.

Thermal Stabilization of ANT(3")(9)
For the thermal stabilization study, the purified enzyme ANT(3")(9) was
incubated with 1 mM of ATP/ ADP/ AMP/AMP-CPP/ AMP-PNP alone or in the
presence of 300 µM of spectinomycin at room temperature for 15 minutes and then
loaded into NanoTemper Tycho standard capillaries. Capillaries loaded into the
instrument NanoTemper Tycho and run.

Results

Arabinose Induction Minimum Inhibitory Concentration
To quantify the change in minimum inhibitory concentration (MIC) upon
induction of the modifying enzymes, we used arabinose inducible pBAD vectors and

23

expressed them in efflux knock-out strains. The advantage of using arabinose inducible
expression vector over the IPTG inducible vectors is that the expression levels of the
protein can be modulated by increasing the concentration of arabinose and repressed by
the addition of glucose.[146] We tested some second-generation amSPCs that showed
promising activity in Gram-negative bacteria and some newer amSPC analogs in these
overexpression strains to characterize their susceptibility to inactivation by the AME
enzymes. Table 2-2 lists the minimum inhibitory concentration for spectinomycin,
amSPC analogs as well as streptomycin upon induction of APH(9)-Ia and ANT(3")(9)
overexpressing E.coli strains. APH(9) induction with 2% arabinose in E.coliΔtolC lead to
an eight-fold increase in MIC for Spectinomycin but no change in MIC for aminomethyl
spectinomycins.[136, 137] Overexpression of ANT(3")(9) causes an increase in MIC of
streptomycin as it is known to adenylate spectinomycin as well as streptomycin.[118, 147]
APH(9)-Ia overexpression did not cause an increase in the amSPC MICs, but ANT(3")(9)
overexpression did increase the MICs for amSPCs. These results indicate that although
amSPCs are not inactivated by overexpression of APH(9)-Ia in Escherichia coli, they are
inactivated by ANT(3")(9) overexpression.

Overexpression and Purification of APH(9)-Ia and ANT(3")(9)
The aph gene of Legionella pneumophila was cloned in Escherichia coli BL21DE(3) with a hexa-histidine tag and expressed and purified the protein. We also similarly
purified the dual-specificity ANT(3")(9) from a clinical isolate of Escherichia coli that
we received from the St. Jude Children's Research Hospital clinic. The purified Aph(9)-Ia
was 38.52 kDa, and purified ANT(3")(9) was 30.90 kDa. The purified proteins on the gel
can be seen in Figure 2-3.

Agar-Based Enzyme Activity Assay
The enzymatic activity of both the purified proteins was checked using a modified
radial agar-diffusion enzyme assay.[148-150] As seen in Figure 2-4A, APH(9)-Ia did
inactivate spectinomycin but not streptomycin; this was in agreement with published
literature and microbial inhibition assay discussed above, that APH(9)-Ia specifically
inactivated spectinomycin only. Interestingly, purified enzyme APH(9)-Ia did inactivate
lead amSPC 2593, while we did not see an increase in the minimal inhibitory
concentration upon overexpression of APH(9)-Ia. To better understand these results, we
reduced the Adenosine 5’-triphosphate concentration in the buffer and noticed that with a
relatively low ATP concentration of 1 mM, APH(9)-Ia did not inactivate amSPC 2593, as
seen in Figure 2-4B. From these results, we concluded that the availability of excess
ATP or the lack of it in the bacterial cells plays a vital role in the ability of these enzymes
to modify and inactivate drugs. ANT(3")(9) inactivated spectinomycin, streptomycin, as
well as amSPC 2593, and this result correlates with our microbial growth inhibition assay
where we saw an increase in the MIC of all three upon overexpression of ANT(3")(9).
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Table 2-2.
Minimum inhibitory concentrations in µg/mL for spectinomycin and
amSPc analogs in E.coliΔtolC and E.coliΔtolC enzyme overexpression strains
Test Compound
Spectinomycin
Streptomycin
1948
1950
2593
4705
4869

E.coliΔtolC
25
12.5
12.5
12.5
3.125
12.5
2.375

E.coli ΔtolC-Ant(3",9)
200
>400
100
100
50
50
50

E.coli ΔtolC-Aph(9)-Ia
200
12.5
12.5
12.5
3.12
12.5
1.62

Figure 2-3. Purified APH(9)-Ia and ANT(3")(9) fractions from affinity and size
exclusion /gel filtration chromatography on SDS -PAGE gel with Coomassie stain
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Figure 2-4.

Agar-based enzyme assay for APH(9)-Ia and ANT(3”)(9)

A. Agar plates showing growth around the disc infused with enzyme and cofactor as the
enzyme inactivates the drug tested. B. APH(9)-Ia with lower ATP concentrations
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MALDI- Mass Spectrometry-Based Enzyme Assay
A MALDI mass spectrometry-based enzyme assay was developed to detect
phosphorylated and adenylated spectinomycin products upon incubation with APH(9)-Ia
and ANT(3")(9), respectively. The mass ion signal for chemically synthesized
phosphorylated spectinomycin with a mass of 413.13 Da and adenylated spectinomycin
hydrate at 680.22 Da was optimized, as shown in Figure 2-5. To clarify the results of
radial diffusion enzyme assay of APH(9)-Ia modifying amSPC 2593, we chemically
synthesized phosphorylated amSPC analogs and optimized their mass ion signals. The
enzymatic reaction setup was modified from Thompson et al.[136] The ability of the
enzyme to phosphorylate different amSPC analogs was checked.
As seen in Figure 2-6, we observed that at least ten times higher concentrations
of APH(9)-Ia was required to detect any phosphorylated amSPCs as compared to
spectinomycin, which helped clarify why we did not see the shift in the minimum
inhibitory concentration of amSPCs upon induction of APH(9)-Ia in vivo but observed
inactivation of amSPCs that at high enzyme and ATP concentrations. A similar reaction
for ANT(3")(9) and amSPCs was not repeated as we already knew from our MIC data
that amSPCs were being inactivated and synthesized adenylated amSPC 2593
biochemically and purified it. We planned on adapting this MALDI -MS-based enzyme
assay for high throughput screening to identify inhibitors of the ANT(3")(9) and APH(9)Ia, so we decided to study the basic kinetics of both the enzymes to help us optimize the
ideal substrate concentrations and incubation periods for both the enzymes. The
enzymatic reaction for APH(9)-Ia was run as described above, and the enzymatic reaction
setup was modified from Kim et al.[144] and % turnovers were calculated. The %
Turnovers were plotted against time to derive velocity or slope graphically, and the
velocity was then plotted against substrate concentration.[151-153] The Km for APH(9)-Ia
for spectinomycin was determined to be 24.10 µM, and the kcat was 4.370 min-1. The
Km and kcat for ANT(3")(9) for spectinomycin Km was 11.59 µM, and the kcat was
17.62 min-1 as seen in Figure 2-7.
The Michaelis-Menten plots of both the enzymes were derived from GraphPad
Prism using the Michaelis - Menten equation. All the Km and kcat values are the mean of
three independent experiments for each of the enzymes. This initial kinetic data for both
the enzymes have helped us determine the substrate concentration required to screen for
inhibitors, for APH(9)-Ia, we will need a substrate concentration of about 25 µM – 30
µM, and the reaction will have to be incubated for 5 minutes at room temperature after
incubation with any potential inhibitors. For ANT(3")(9), the ideal substrate
concentration of about 10-20 µM, and the reaction time will be 20 minutes at room
temperature. The optimal time for incubation with the inhibitor will vary from the
substrate incubation times for both the enzymes.
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Figure 2-5. Signal optimization for spectinomycin, phosphorylated spectinomycin,
and adenylated spectinomycin

Figure 2-6. Effect of varying concentrations of APH(9)-Ia on spectinomycin and
amSPC analogs
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Figure 2-7. Michaelis-Menten plots of APH(9)-Ia and ANT(3")(9) against
spectinomycin plotted in Prism
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Structural Analysis of ANT(3")(9) Bound to AMPPNP and Spectinomycin
The crystal structure of ANT(3")(9) from Salmonella enteritica has been solved,
and to check the similarity between the two enzymes, a sequence alignment of
Salmonella enteritica ANT(3”)(9) (UNIPROT ID Q8ZPX9) was performed using the
NCBI blast tool[154, 155], and identity was found to be 45.38 % only. We similarly did a
sequence alignment of known ANT(3")(9) from different species, and the closest match
was the dual-specificity enzyme from Enterococcus faecalis (Uniprot IDQ71UU1)
alignments are shown in Figure 2-8. The crystal structure of ANT(3")(9) bound to
substrate spectinomycin, and an artificial analog of adenosine 5'- triphosphate (ATP)
adenylyl-imidodiphosphate (AMP-PNP) was solved. ANT (3")(9) is a globular protein
whose tertiary structure is made up of eight alpha-helices supporting a single five-strand
beta-sheet, as seen in Figure 2-9. The enzyme's active site that forms spectinomycin and
AMP-PNP binding sites is coordinated between two magnesium ions. In its hydrated
form, Spectinomycin stacks approximately 3.8Å from the Trp108 side chain and make
dual hydrogen bonding interactions with Asp178 side-chain, one direct hydrogen bonding
interaction with Asn181, one water-mediated hydrogen bond with Lys201, and several
hydrogen-bonding interactions with coordinated active site waters see Figure 2-10A.
The C9 hydroxyl group that becomes adenylated by this enzyme coordinates with
an Mg2+ ion that is coordinated in a total of 6 interactions with active site water, the
alpha-phosphate of AMP-PNP, Asp43, Asp45, and Glu83 side chains see Figure 2-10B.
The alpha phosphate of AMP-PNP also coordinates the 2nd Mg2+ ion that most closely
coordinates the binding of the AMP-PNP cofactor. This ion also forms 6 coordinated
interactions with the alpha-, beta- and gamma-AMP-PNP phosphates and Asp43 and
Asp45 side chains, and active site water that coordinates with the Asp43 backbone
carbonyl as seen in Figure 2-11A. In addition to their roles coordinating the Mg2+ ions,
the AMP-PNP phosphates form additional interactions with the active site and active sites
waters. The alpha phosphate forms a 3.0Å hydrogen bond with Lys201 and a watermediated interaction with Lys133. The beta-phosphate forms a 2.8Å h-bonding
interaction with Arg188, and the terminal gamma phosphate forms three additional
hydrogen-bonding interactions with the side chains of Ser47, Tyr227, and Lys201.
In addition to the AMP-PMP phosphates being highly coordinated with the active
site magnesium ions, the adenosine and ribose are also highly coordinated with the
protein, where the adenosine amide forms a 3.0Å interaction with Ser192, and the
adjacent ribose alcohols form dual hydrogen bonding interactions (2.8, 2.7Å) with the
Asp126 side chain as seen in Figure 2-11B.

Thermal Stabilization of ANT(3")(9)
ANT(3")(9) was incubated with ATP or ATP analogs in the presence and absence
of spectinomycin, and the melting temperature of the enzyme under each condition was
noted to understand the stabilization effect each of these had on the enzyme.
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Figure 2-8. Protein sequence alignment of ANT(3”)(9) from different bacterial species against aadA13 encoded ANT(3”)(9)
from Escherichia coli isolate 5 as the query 5638
5638- aadA13 encoded ANT(3”)(9) from Escherichia coli isolate 5 5636-ANT(3”)(9) from Enterococcus faecalis (Uniprot ID
Q71UU) at the top 100% identity followed by 5640 -Pseudomonas aeruginosa (Uniprot ID Q9RGC2) with 76.36% identity, 5639 Serratia marcescens (Uniprot ID Q8VQN7) with 75.58% identity, 5637 - Salmonella enteritica var typhimurium (Uniprot ID
Q8ZPX9) with 45.38% and 5541 – ANT(9) from Enterococcus faecalis(Q07448) had only 38% identity, this enzyme adenylates
spectinomycin alone. Blue highlighted residues are highly conserved residues, and the lighter green highlighted residues are least
conserved across species.
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Figure 2-9. Crystal structure of ANT(3")(9) bound to adenylyl-imidodiphosphate,
magnesium, and spectinomycin
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Figure 2-10. Interactions of ANT(3")(9) with spectinomycin in the binding site
Panel A showing spectinomycin interactions with ANT(3")(9) active site amino acid
residues, and Panel B shows the interaction of spectinomycin with active site residues
and magnesium ions.
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Figure 2-11. Interactions of ANT(3")(9) with AMP-PNP and magnesium in the
binding site
Panel A shows the interaction of magnesium ions the active site amino acid residues, and
Panel B shows the interaction of phosphates of adenylyl-imidophopshate with the active
site residues.
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The melting was calculated by monitoring the intrinsic fluorescence of the amino
acids - tryptophan and tyrosine in the protein as it is unfolded using Nanotemper Tycho.
In the absence of spectinomycin, ATP did not appear to stabilize the protein much as the
only one-degree shift was observed upon incubation with ATP alone, as seen in
Figure 2-12. Similarly, adenosine diphosphate (ADP) did not show much stabilization
either; adenosine monophosphate (AMP) and adenylyl imidophopshate (AMP-PNP)
exhibited better stabilization than ATP in the absence of spectinomycin. Upon the
addition of spectinomycin, these patterns changed.
The addition of spectinomycin to the enzyme and ATP mix increased the melting
temperature by over 40C, indicating stabilization of the ANT(3")(9). The only ATP
analog to stabilize the enzyme was AMP-PNP. The formation of crystals with AMP-PNP
and spectinomycin bound further confirms the stabilization we observed here. AMP-CPP,
another synthetic ATP analog, did not appear to stabilize ANT(3")(9) at all in the
presence of spectinomycin. The stabilization initially seen with AMP did not increase
upon addition of spectinomycin to the AMP -ANT(3")(9) mix, indicating that AMP
binding to ANT(3")(9) was bringing about the conformation change required for
spectinomycin binding. We also tested the ability of all the ATP analogs tested here to
adenylate spectinomycin in our MALDI mass spectrometry-based enzyme assay, and we
detected adenylated spectinomycin upon incubation with all the analogs except AMP and
AMP-CPP.

Discussion
Aminoglycosides are broad-spectrum antibiotics developed to treat infections
caused by Gram-negative bacteria.[142] Aminocyclitols are a part of this larger group, and
spectinomycin and streptomycin belong to this group.[163] The major toxicity issues that
aminoglycosides suffer from are nephrotoxicity and ototoxicity[142]; spectinomycin does
not cause these two toxicities.[164, 165] The safety profile and lack of hepatic metabolism
provide strong support for revisiting spectinomycin and developing newer analogs that
exhibit better inhibitory activity against Gram-negative bacteria. This approach was
adopted, and aminomethyl spectinomycins were synthesized, and their ability to inhibit
the growth of respiratory tract pathogens like Streptococcus pneumoniae and Legionella
pneumophila was established.[133, 135] Looking at the literature evidence of how critical
aminoglycoside modifying enzymes play in imparting resistance to aminoglycosides,
including spectinomycin, our goal for this study was to characterize the susceptibility of
second-generation aminomethylspectinomycins to spectinomycin specific
aminoglycosides. From our previously published results of amSPCs inhibiting the growth
of Legionella pneumophila, we hypothesized that amSPCs were not getting inactivated
by aminoglycoside modifying enzymes.[133] To check our hypothesis, we cloned and
overexpressed the aph gene encoding APH(9)-Ia enzyme from Legionella pneumophila
in an efflux knock-out strain of Escherichia coli to ensure any increase in the minimum
inhibitory concentration of amSPC noted was not due to efflux and only due to
inactivation by APH(9)-Ia expression.[138]
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Figure 2-12. Change in melting temperatures of ANT(3")(9) upon addition of ATP
or its analogs alone and in the presence of spectinomycin
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The minimum inhibitory concentration of spectinomycin increased eight-fold
upon induction of the aph gene with 2% arabinose, but no change in the minimum
inhibitory concentration of streptomycin was observed in Table 2-2, thus confirming the
substrate specificity of APH(9)- Ia reported in the literature.[118, 136] We did not notice
any increase in the minimum inhibitory concentration upon induction of the aph gene
using up to 2% arabinose, leading us to conclude that amSPCs were not being inactivated
by APH(9)-Ia. We then decided to test the ability of spectinomycin adenylating enzymes
to adenylate amSPCs. Spectinomycin adenylating enzyme ANT(9) found in
Enterococcus faecalis was already shown to adenylate spectinomycin, and its crystal
structure bound to spectinomycin has recently been solved by Kanchugal et al.
ANT(3")(9) is more widely distributed across Gram-positive and Gram-negative
bacteria.[145, 166] We received some multi-drug resistant Escherichia coli strains from the
St Jude Children's Research Hospital clinic and sequenced them to identify the resistance
imparting genes. We learned that four out of six clinical isolates sequenced carried dualspecificity spectinomycin/streptomycin adenylating enzymes by running them through
the CARD database.[143] We cloned the aadA13 gene from Escherichia coli clinical
isolate 5 encoding for ANT(3")(9) enzyme (sequence 5638 in Figure 2-8) into the efflux
knock-out strain that we had used earlier for APH(9)-Ia overexpression. We tested the
minimum inhibitory concentration of spectinomycin as well as amSPCs. Upon induction
on the aadA13 gene with 2% arabinose, we noted an increase in the minimum inhibitory
concentration of spectinomycin, streptomycin, and amSPCs, indicating that all three were
being inactivated by ANT(3")(9).
To study the biochemical activity of both the aminoglycoside modifying
enzymes- APH(9)-Ia and ANT(3")(9), we expressed them in Escherichia coli BL21
expression strains and purified them. To ensure that the purified proteins were
enzymatically active, we used a simple agar-based enzyme activity assay. We noticed
that in the presence of lower concentration adenosine-triphosphate or ATP, APH(9)-Ia
was not inactivating amSPCs, but it was inactivating spectinomycin. Upon increasing the
concentration of ATP, we noted some inactivation of amSPC by APH(9)-Ia. This assay
also revealed that the purified ANT(3")(9) enzyme was inactivating spectinomycin,
streptomycin (see Figure 2-4), as has been reported previously in the literature.[144, 166, 167]
To enable us to detect and quantify the adenylated products of spectinomycin and
amSPCs, we used the MALDI mass spectrometry-based enzyme activity assay. We used
this assay to detect phosphorylation of amSPCs if any and observed that about ten times
higher concentration of the purified enzyme APH(9)-Ia was required to start detecting
phosphorylated amSPC compared to spectinomycin as observed in Figure 2-6. We
believe the intracellular concentrations of APH (9)-Ia and freely available ATP are not
high enough in Legionella pneumophila or Escherichia coli to enable modification and
inactivation of amSPC. We also used this assay to study the preliminary steady-state
kinetics of APH(9)-Ia, which would enable us to validate this assay. The MichaelisMenten constant (Km) we calculated for APH(9)-Ia in Figure 2-7 agreed with previously
reported Km by Thompson et al. calculated using a well-established colorimetric assay
still used to study the kinetics of aminoglycoside modifying enzymes.[136, 157, 168] The
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advantage of using the mass spectrometry-based enzyme assay is the ability to quantify
the enzyme activity as a function of percent turnover calculated using the substrate and
phosphorylated product instead of relying on quantifying the ADP released as a
byproduct of the enzymatic reaction. The assay is adaptable to high throughput screening
in case of a need to screen for inhibitors, and Wu et al. have described the details of using
the steady kinetics of an enzyme to determine substrate concentrations for high
throughput screening assays.[151]
We used the mass spectrometry-based enzyme assay to detect adenylated
spectinomycin and amSPC as a result of ANT(3")(9) activity as we already knew that
ANT(3")(9) was adenylating and inactivating amSPCs. We also determined the
preliminary steady-state kinetics, intending to use the information in developing a high
throughput screening assay to identify inhibitors. We now know that the substrate
concentration of about 10-20 µM and incubation time of 20 minutes for ANT(3")(9)
would be ideal for planning our high throughput inhibitor screen.
Crystal structure of APH(9)-Ia in Apo form and bound to ADP and
Spectinomycin were already solved by Fong et al. providing insights about critical
interactions with the spectinomycin in the active site that impart the stringent substrate
specificity to the enzyme.[137] This enzyme lacks a negatively charged antibiotic binding
pocket conserved in other aminocyclitol modifying enzymes like APH(3')-IIa or
APH(2")-IIa. APH(3')-IIa alone phosphorylates kanamycin, paromomycin, butirosin,
neomycin, and gentamicin.[147] Crystal structures of spectinomycin and streptomycin
adenylating enzyme ANT(3")(9) from Salmonella enteritica serovar Typhimurium and
ANT(9) from Enterococcus faecalis, which adenylates spectinomycin alone have been
solved.[167, 169] To determine the similarity of the aadA13 encoded ANT(3")(9), we did a
sequence alignment of all three enzymes using the NCBI blast tool. We discovered that
there was only a 45.38% sequence identity with Salmonella enteritica encoded
ANT(3")(9) and 32.60% with Enterococcus faecalis encoded ANT(9).
We successfully crystallized ANT(3")(9) bound to adenylyl-imidodiphosphate
(AMP-PNP), a synthetic analog of ATP and spectinomycin see Figure 2-8. In their study
of the structural mechanism of aadA from Salmonella enteritica, Stern et al. reported that
they did not detect binding of synthetic ATP analogs AMP-CPP or AMP-PNP to the
enzyme.[170] This observation emphasizes that although both enzymes adenylate
spectinomycin and streptomycin, the differences in their amino acid sequences impart
unique abilities to accommodate and utilize different adenyl group donors to adenylate
the substrate. We not only detected binding of AMP-PNP but also observed that aadA13
encoded ANT(3")(9) could use AMP-PNP as a donor for the adenylyl group to modify
spectinomycin in the absence of ATP. In our quest to identify ATP analogs that bind and
stabilize the conformation of ANT(3")(9) to allow for spectinomycin binding and design
a binding affinity assay, we tested the ability of ADP, AMP-PNP, and AMP-CPP to bind
and stabilize ANT(3")(9). The stabilization for ANT(3”)(9) order was found to be AMPPNP > Ad-spectinomycin >ATP > ADP > AMP. We also ran the enzyme assay with all
the ATP analogs and detected adenylated spectinomycin products with ADP and AMPPNP. The two ATP analogs most stabilizing ANT(3")(9) were was adenylating the
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spectinomycin, so any binding affinity reported would be the binding affinity of the
adenylated product and the leaving pyrophosphate group rather than the substrate. We
thus concluded that the best way to develop a binding affinity assay would be to use an
enzymatically inactive mutant ANT(3")(9). We are now better equipped to make the
enzymatically inactive mutant with the crystal structure's critical active site residue
interactions.
The crystal structure will also be a useful tool for in silico docking of possible
inhibitors and also structure-based designing of newer amSPC analogs that can overcome
modification by ANT(3")(9). A recent study, structure-guided optimization to develop
acetyltransferase inhibitors in Mycobacterium tuberculosis by Punetha et al., highlights
how crystal structures can play a critical role in guiding the development of
aminoglycoside modifying inhibitors.
In our quest to characterize the susceptibility of amSPCs to modification by
aminoglycoside modifying enzymes, we developed a platform to check the susceptibility
of amSPC analogs, including a panel of enzyme overexpression strains to check wholecell susceptibility and calculate the minimum inhibitory concentrations and biochemical
assays. The mass spectrometry-based biochemical assays to check the susceptibility of
modification by purified enzymes can easily be adapted to a high throughput screening
format to screen for inhibitors of these enzymes. We also successfully solved the crystal
structure of ANT(3")(9) and learned the critical active site interactions between the
enzyme, substrate, and cofactors. These platforms will not only enable characterization of
newer amSPC analogs as they are being synthesized but also help design analogs that can
overcome modification and identify inhibitors of the more widely distributed and
challenging to overcome ANT(3")(9) enzymes.

39

CHAPTER 3. HIGH THROUGHPUT SCREEN TO IDENTIFY SMALL
MOLECULES THAT POTENTIATE EFFICACY OF LEAD amSPC 2593

Introduction and Background
In chapter 2, we checked the susceptibility of aminomethyl spectinomycins to
modification and inactivation by aminoglycoside modifying enzymes. We observed that
although they overcame modification by APH(9)-Ia enzyme in Legionella pneumophila,
they were being subjected to modification and inactivation by ANT(3")(9) in the
overexpression Escherichia coli ΔtolC strain. Modification by antibiotic inactivating/modifying enzymes is one of the many mechanisms of resistance that bacteria possess, as
we already discussed in chapter 1. This chapter focuses on two other critical resistance
mechanisms of bacteria, poor drug penetration through cell membranes and cell walls
seen especially in the case of Gram-negative bacteria and expulsion of drug molecules
through efflux pumps.
As discussed in chapter 1, the Gram-negative bacterial envelope is impermeable
mainly due to lipopolysaccharide. The role of lipopolysaccharide in Gram-negative
bacterial resistance has been established in Pseudomonas aeruginosa, Vibrio cholerae,
and Brucella spps. The arrangement of glycerophospholipids in the inner leaflet and
lipopolysaccharide in the outer leaflet imparts very little fluidity to the outer membrane.
So far, only cationic peptides and chelators have shown successful perturbation of the
outer membrane, making Gram-negative bacterial infections extremely difficult to
treat.[81, 85, 86, 171, 172] The outer membrane porins are water-filled channels that span the
outer membrane; OmpF and OmpC of Escherichia coli allow hydrophilic molecules
smaller than 650 Da to be transported through them; small hydrophobic molecules diffuse
through the lipid bilayer.[84, 173, 174] Porins Opr D and Opr F of Pseudomonas aeruginosa
allow larger molecules up to 3000 Da to pass through them, but still, the permeability of
the outer membrane of P.aeruginosa is only about 8% of Escherichia coli.[81, 175]
Mutation in porin encoding genes in response to antibiotics entering the Gram-negative
via porins has already been reported in several bacteria, including Escherichia coli,
Pseudomonas aeruginosa Klebsiella pneumoniae.[81, 176-178]
We also discussed the five types of efflux pumps in bacteria and their role in
imparting resistance to antibacterials. The most relevant family in Gram-negative bacteria
in imparting resistance are the Resistance Nodulation Division (RND) efflux pumps.
These pumps are known to be overexpressed in the presence of antibacterial pressure.
The notable RND pumps involved in imparting resistance are AcrAB-TolC from
Escherichia coli and MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM,
MexJK-OprM, MexGHI-OprD, and MexVW-OprM from Pseudomonas aeruginosa.[81,
102, 179-182]
The natural function of the bacterial RND pumps is believed to pump out
environmental toxins; homologs of RND pumps are believed to spread across Grampositive bacteria and archaea.[81, 183] The RND efflux pumps also play a role in the efflux
of signal molecules in quorum sensing; MexEF-OprN of Pseudomonas aeruginosa is
involved in releasing a quinolone signaling molecule PQS (Pseudomonas Quinolone
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Signal), and that explains its involvement in the efflux of quinolone antibiotics.[184, 185]
The AcrAB pump of Escherichia coli has a very high affinity for bile salts; as the
bacteria is a part of normal gut microflora, the inherent ability to protect itself from bile
salts is required for survival in the human gut.[186]
To check the susceptibility of amSPCs to being effluxed out of cells and poor
outer membrane penetration, we requested our collaborators at the University of
Colorado, Dr. Helen Zgurskaya's laboratory. They tested the amSPC in a hyperporinated
Escherichia coli expressing a modified FhuA porin- a siderophore transporter. The Nterminal of FhuA (shown in Figure 3-1) is selective to binding siderophores to transport
iron inside the bacterial cell from the environment.[174] Upon removing this selective Nterminal domain, FhuA becomes a barrel-like protein across the membranes that allows
larger molecules to enter the bacterial cell.[174, 187]
The idea is that if the minimal inhibitory concentration of a drug or test molecule
is reduced upon expression of the FhuA porin, they are being subjected to poor
penetration or are just too large to enter the bacterial cell through outer membrane porins
expressed in the bacterial cell envelope. In addition, they also tested the amSPC analogs
in tolC and ygiBC knocked out strains of Escherichia coli. TolC and YgiBC are both
transporters involved in the efflux; TolC functions in association with AcrAB efflux
pumps; YgiBC has overlapping substrate specificities with TolC and thus was knocked
out to eliminate any contribution efflux.[188] The minimal inhibitory concentrations of all
the amSPCs decreased upon overexpression of the mutated FhuA porin, indicating that
when porins that allow larger hydrophilic molecules to pass through are expressed, the
ability of amSPCs to enter the bacterial cell and inhibit growth improves (see Table 3-1).
The MICs of amSPCs also decreased, knocking out the efflux pumps, thus indicating that
the amSPCs were being pumped out of the bacterial cells. The preliminary analysis
results by Dr. Zgurskaya's group indicated that although not as much as spectinomycin,
amSPCs were suffering from efflux and were limited by their size to pass through the
outer membrane porins. These results led to the start of search for potentiators of
amSPCs.
Combination therapy with antibiotics and non-antibiotic-potentiating adjuvants
have been around for a while as the problem of resistance in bacteria rises, especially in
Gram-negative bacteria. One of the best examples of this combination is the β-lactams
and the β-lactamase inhibitors like amoxicillin and clavulinic acid.[189] Bernal et al. have
described examples of potentiators and antibiotics like the combination of colistin with
Rifampicin.[190] Short proline-rich lipopeptides help minocycline gain inhibitory activity
against Gram-negative bacteria like multidrug-resistant Pseudomonas aeruginosa regain
activity in resistant Gram-positive bacteria.[191] Looking at the literature evidence of the
success of combination therapy, we decided to take the high throughput screening
approach to identify potentiators of amSPC. The workflow included a high throughput
screening of Gram-negative bacteria-focused polar library at St. Jude Children's Research
Hospital in the whole-cell clinical isolates, confirming the single point hits with a doseresponse curve fitting.
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Figure 3-1. Dimensional structure of FhuA porin (a) front view, (b) top view
showing the N-terminal domain-specific for siderophores to import iron from the
environment
Reprinted with permission from John Wiley and Sons. Ferguson, A.D., et al., The Ferric
Hydroxamate Uptake Receptor FhuA and Related TonB-Dependent Transporters in the
Outer Membrane of Gram-Negative Bacteria, in Handbook of Metalloproteins. 2006.
DOI: 10.1002/0470028637.met160.

Table 3-1.
Minimum inhibitory concentrations of amSPCs in hyperporinated
and efflux knock out strains as compared to wild type

Drug
amSPC 1950
amSPC 2462
amSPC 2468
amSPC 1980
amSPC 2593

Minimum Inhibitory Concentrations in µg/mL in E.coli Strains
Wild type
Reduced Reduced Efflux &
with
Hyperporination
Efflux
Hyperporination
Vector
50
6.25
3.125
1.56
25
3.125
1.56
0.78
>50
25
12.5
6.25
25
6.25
3.125
1.56
25
6.25
3.125
1.56
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Then use the hyperporinated and efflux knock-out strains to narrow down the
rules of penetration or mode of entry of the potentiators and then generate resistant
mutants to identify the mechanism of potentiation action. Dr. Kim Lewis has described
the workflow and benefits of the high throughput screening approach for combination
therapies in his review article in 'The platforms for antibiotic discovery' very well.[64] He
describes high throughput screening as a new platform to identify and generate new leads
and the study of penetration rules as a new tool that can develop new therapies and aid in
rational drug designing. These relationships between the tools and platforms are
summarized in Figure 3-2.

Materials and Methods

Assay Validation with Known Bioactive Library in Bioluminescent Escherichia coli
Xen14
Our high throughput screening platform was validated using the Bioactive library,
which included known antibacterial compounds and other known drugs in a 384-well
format. Six source plates of the Bioactive Library were requested from the Compound
Management group in the Chemical Biology and Therapeutics Department at St. Jude
Children's Research Hospital. The amSPC 1950 and 2593 were synthesized by the
chemists in our laboratory.[133, 135] We added 10 µg/mL of amSPC 1950 to the cationadjusted Mueller Hinton broth, and 26 µL of this was dispensed in optical bottom Nunc
384-well plates using the liquid dispenser WellMate. We used the 100SS pin tool with
Biomek to stamp 121 nL of drug from the Bioactive library into each plate twice. The
final concentration of the bioactive compound in each well was 10mM. Stocks were
made from bacteria grown to 0.60 optical density, which translated to 2.11 X 109 CFUs.
The bacteria were inoculated at 0.01 optical density in assay plates to reach maximum
luminescence at 8 hours. Luminescence was read at the end of 8 hours using a Pherastar
microplate reader. The luminescence reading endpoint of 8 hours was optimized using a
Pherastar microplate reader to check luminescence every 30 minutes while incubating the
bacteria at 370 C. The optimal luminescence read time was found to be 8 hours. No
induction was needed as the lux genes are constitutively expressed in the bacterial strains.
Dimethyl sulfoxide was the negative control, and colistin was the positive control used.

amSPCs Activity Against Clinical Isolates of Escherichia coli and Genome
Sequencing
We received six Escherichia coli strains isolated from the patient samples from
the St. Jude Children's Research Hospital Clinic. We used broth microdilution assay to
determine the minimal inhibitory concentration of spectinomycin and amSPCs in the
clinical isolates of Escherichia coli. The genomic DNA was extracted using Qiagen
maxiprep DNA extraction kits. The extracted DNA was submitted to Hartwell Center –
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Figure 3-2. Relationship between platforms and tools for high throughput
screening for combination therapies
Modified with permission from Springer Nature. Lewis, K., Platforms for antibiotic
discovery. Nature Reviews Drug Discovery, 2013. 12(5): p. 371-387.
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the sequencing core in Shared Resources at St. Jude Children's Research Hospital for
Illumina Hi-Seq paired multiplex sequencing. The raw data received was used for
genome assembly in CLC- Genomics Workbench. The assembled genomes were
submitted to the Comprehensive Antibiotic Resistance Database (CARD) to identify the
clinical isolates' resistance genes.[143]

Polar Library Screen for Potentiator of amSPC 2593 Against Escherichia coli isolate
5, and Escherichia coli isolate 1
The Polar Library plates- 48 plates, in 384-well format were requested from the
Compound Management group in the Department of Chemical Biology and Therapeutics
at St. Jude Children's Research Hospital. The amSPC 2593 was synthesized by the
chemists in our laboratory. We added 10 µg/mL of amSPC 1950 to the cation-adjusted
Mueller Hinton broth, and 13 µL of this was dispensed in optical bottom Nunc 384-well
plates using the liquid dispenser WellMate. We used the 100SS pin tool with Biomek to
stamp 121 nL of drug from the Polar library into each plate once. The final concentration
of the polar library compound in each well was 10mM. Stocks were made from bacteria
grown to 0.60 optical density, which translated to 2.11 X 109 CFUs; these stocks were
then diluted 10-3 in cation adjusted Mueller Hinton broth containing 10 µg/mL of amSPC
2593. 13 µL of this diluted culture was then added to each well of the assay plate. The
plates were incubated at 370 C with 5% CO2 for 16 hours. The plates were allowed to
equilibrate at room temperature for 30 minutes before reading adding 26 µL of BacTiter
Glo™ and reading the luminescence read using a Pherastar microplate reader. The raw
data acquired was uploaded to the RISE protocol of Pipeline Pilot to calculate the %
growth inhibition and Z' factor to ensure the robustness of the screen.
For the dose-response curve fitting, the dose-response plates of the single-point
hits were requested from Compound Management. We added 10 µg/mL of amSPC 1950
to the cation-adjusted Mueller Hinton broth, and 13 µL of this was dispensed in optical
bottom Nunc 384-well plates using the liquid dispenser WellMate. We used the 100SS
pin tool with Biomek to stamp 121 nL of drug from the Polar library into each plate once.
The final concentration of the polar library compound in each well was 10mM. Stocks
were made from bacteria grown to 0.60 optical density, which translated to 2.11 X 109
CFUs; these stocks were then diluted 10-3 in cation adjusted Mueller Hinton broth
containing 10 µg/mL of amSPC 2593. 13 µL of this diluted culture was then added to
each well of the assay plate. The plates were incubated at 370 C with 5% CO2 for 16
hours. The plates were allowed to equilibrate at room temperature for 30 minutes before
reading adding 26 µL of BacTiter Glo™ and reading the luminescence read using a
Pherastar microplate reader. The raw data acquired was uploaded to the RISE protocol of
Pipeline Pilot, and the dose-response curve fitting option was selected to analyze the data
and generate the curves.
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Results

Assay Validation with Known Bioactives in Bioluminescent Escherichia coli Xen14
We started our screening for potentiators of amSPCs efforts by testing a smaller
known bioactive compounds library, which consisted of some known antibacterials to
ensure the validity of our assay platform. The Escherichia coli strain we started screening
against was bioluminescent E.coli xen14 encoding a constitutively expressed lux operon
from Photorhabdus luminescens. The reduction of luminescence as the test compound
inhibited bacterial growth compared to the negative control calculated the % growth
inhibition. We started our screening efforts with amSPC 1950, our first-generation
amSPC lead. The minimum inhibitory concentrations of amSPC 1950 and amSPC 2593
alone against E.coli xen14 were 50 µg/mL, and we used 5X lower concentrations (10
µg/mL) than the minimum inhibitory concentration to check for potentiation. The amSPC
1950 was added to the medium itself before the stamping of 50 µM of Bioactive
compounds to the wells. The cutoff for potentiation activity was set to 90% growth
inhibition. We identified 33 hits that exhibited 90% growth inhibition; see the scatter plot
in Figure 3-3. We then tested the bioactive library without amSPC in the medium and
identified four hits that exhibited less than 70% inhibition without amSPCs in the
medium (see Table 3-2). The robustness of the screen was measured by calculating the Z'
score[193] and found to be between 0.45 - 0.7 for all assay plates. 10 µg/mL
chloramphenicol was a positive control, and DMSO was the negative control. The %
growth inhibition was calculated using Equation 3-1. Since the objective is to identify
potentiators of amSPCs, the potentiator molecules not having growth inhibitory activity
by themselves were desirable. These results also validated our assay setup, and we were
ready to screen the larger Polar library.
𝑍 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −

3(𝜎𝑝 +𝜎𝑛 )
|𝜇𝑝 −𝜇𝑛 |

(Eq. 3-1)

σp and σn in Equation 3-1 are the standard deviations of positive and negative controls
respectively; µp and µn are the means of positive and negative controls respectively.

amSPCs Activity Against Clinical Isolates of Escherichia coli and Genome
Sequencing
We received multi-drug resistant clinical isolates of Escherichia coli from the St.
Jude Children's Research Hospital clinic while planning our screen for potentiators. We
checked the minimum inhibitory concentration of amSPC 2593, our second-generation
lead against the clinical isolates, and observed that amSPCs were not inhibiting the
growth of these isolates at 200 µg/mL concentrations. The minimum inhibitory
concentrations of spectinomycin for all the clinical isolates of Escherichia coli received
are listed in Table 3-3. The genomes of these six Escherichia coli clinical isolates were
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Figure 3-3. Scatter plot of % growth inhibition over the Bioactive library and
amSPC 1950

Table 3-2.
Hits from the Bioactive library for amSPC 1950 potentiator for
bacterial growth inhibition
Potentiator
Name
Floxuridine
Rifaximin
Balofloxacin
PIK-294

Activity
Anticancer
Antidiarrheal
Antibacterial
Anticancer

% Growth Inhibition
With amSPC 1950
97.25
97.28
100.00
100.00
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% Growth Inhibition
Without amSPC 1950
0.00
62.00
65.00
0.00

Table 3-3.
Minimal inhibitory concentration of spectinomycin in clinical isolates
of Escherichia coli and the aminoglycoside modifying gene (AME) encoded in their
genomes
E.coli
Strains
E.coli Xen 14

Spectinomycin
MIC (µg/mL)
50

amSPC 2593
MIC(µg/mL)
50

E.coli CI1

50

50

APH(3") and APH(6)-Ib

E.coli CI2

50

50

No AMEs

E.coli CI3

>200

>200

ANT(3”)(9)

E.coli CI4

>200

>200

ANT(3”)(9)

E.coli CI5

>200

>200

ANT(3”)(9)
[aadA13 and aadA5]

E.coli CI6

100

>200

ANT(3”)(9)
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AME Encoded in Genome
Not Applicable

sequenced to identify the resistance genes encoded in the genomes. The CARD database
was used to identify the genes encoding for resistance factors.[143] CARD or
Comprehensive Antibiotic Resistance Database is a peer-reviewed and curated collection
of resistance factors and has tools for analyzing bacterial sequences to identify the
resistance factors. Each clinical isolate encoded multiple resistance genes that impart
resistance by modifying the target or pumping out the antibiotic via efflux pumps or
modifying and inactivating the antibiotic. A snapshot of Escherichia coli isolate 5's
resistance imparting genes and Escherichia coli isolate 1 can be seen in Figures 3-4 and
3-5, respectively.
The isolates carry multiple efflux pump encoding genes, including the RND
family of efflux pumps common to Gram-negative bacteria. The other families of efflux
pump common in both the clinical isolates were the major facilitator superfamily(MFS)
pumps and ATP binding cassette (ABC) family and the Small Molecule Resistance
(SMR) efflux pump. Apart from efflux pumps, both the isolates also had antibiotic target
alteration genes, which either encode proteins that alter the target of the antibiotics or are
the target genes with mutations in them that alter the binding site of the antibiotics. Both
the isolates also carried genes that encoded for antibiotic inactivating enzymes. One
significant difference between the isolates' resistance factors was that Escherichia coli
isolate 1 did not carry any spectinomycin modifying enzyme encoding genes, which was
reflected in the minimum inhibitory concentration of spectinomycin for this isolate.
Spectinomycin had a much lower minimum inhibitory concentration in Escherichia coli
isolate 1 than Escherichia coli isolate 5, which had two genes encoding spectinomycin
adenylating enzymes- aadA5 and aadA13. The genes highlighted in bold red font are the
ones that had point mutations in them.

Polar Library Screen for Potentiator of amSPC 2593 Against Escherichia coli isolate
5, and Escherichia coli isolate 1
We decided to use the Escherichia coli isolate 5 for the potentiator screening as it
had aadA13 encoding ANT(3")(9) that was inactivating spectinomycin and amSPC. The
aadA13 gene was cloned, expressed, and purified to study its biochemical activity on
spectinomycin and amSPCs. The polar library chosen to be screened for potentiators
consisted of about 16000 compounds with a log P of less than 2 and hence more likely to
cross the Gram-negative bacterial outer membrane barrier. We decided to move from
amSPC 1950 to amSPC 2593, our second-generation amSPC lead compound, which
showed improved inhibitory activity over amSPC 1950 in most Gram-negative bacteria
tested. Since the Escherichia coli isolate 5 was not autoluminescencing, we added
BacTiter Glo™ from Promega to quantify luminescence at the end of the incubation
period. BacTiter Glo™ detects viable microbial cells based on quantification of ATP
present. The decrease in luminescence as compared to negative controls indicates growth
inhibition. As the polar library was significantly more extensive than the bioactive
library, we used the Robust Interpretation of Screening Experiments (RISE) protocol in
Pipeline Pilot (Accelrys, v. 8.5) to analyze the data, generate scatter-plots, and calculate
Z' to check the robustness of the screen.[158] The inhibitory activity cutoff was 30% due to
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Figure 3-4. The resistance genes of Escherichia coli isolate 5, classified by
mechanism of resistance imparted and the efflux pump families
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Figure 3-5. The resistance genes of Escherichia coli isolate 1, classified by
mechanism of resistance imparted and the efflux pump families

51

the highly resistant nature of the bacteria, i.e., any compound that inhibited the bacterial
growth by 30% was considered a hit. We identified 43 hits, out of which 23 were known
antibiotics. We similarly screened the polar library against Escherichia coli isolate 1,
which did not possess any aadA gene or ANT(3")(9) enzyme and thus was not as
resistant to spectinomycin or amSPC as the other isolates. The scatter plots generated by
the RISE protocol for Escherichia coli clinical isolate 5 screen are in Figure 3-6 and for
Escherichia coli isolate 1 screen, Figure 3-7. We raised the activity cutoff to 40% for
Escherichia coli isolate 1 as it lacked the aadA gene and identified 79 hits, out of which
24 were known antibiotics.

Dose-Response Curve Fitting for the Single Point Hits from Escherichia coli isolate 5
Screen
Our goal was to identify non-antibiotic potentiators, so we first focused on getting
a dose-response of the novel hits from the Escherichia coli isolate 5 screen and then the
known antibiotics. The highest concentration of potentiators for the dose-response plates
was 10 mM, and the concentration was amSPC was kept constant at 10 µg/mL.
Figures 3-8 to 3-11 summarize the dose-response curves generated again by using the
RISE protocol of Pipeline Pilot. The RISE protocol output classified the dose-response
curves into classes A, B, C, and D based on the quality of the curve fitting; we chose the
class A curve fits, which had the goodness of fit or R2 values of 0.9 or above as our doseresponse hits. Out of 20 single-point hits tested in dose-response for potentiation,12
compounds showed good dose-response curve fit and had EC50 ranging from 1.2 µM –
42.84 µM. These 12 confirmed hits will be tested for any synergizing amSPC activity in
the clinical isolates. These 12 compounds will also be tested against hyperporinated and
efflux knock-out strains from Dr. Zgurskaya's laboratory to identify the rules of
penetration. The 23 known antibiotics were also tested for dose-response curve fits. Class
A curves, which had the goodness of fit or R2 values of 0.9 or above, were chosen as
dose-response hits. 5 out of the 23 tested met the criteria and were selected as doseresponse confirmed hits.
The curve fits are summarized in Figures 3-12 and 3-13, and the EC50 for these
ranges between 0.25 µM to 2.2 µM. These results helped us narrow down possible
potentiators to 12 non-antibacterial compounds and 5 potentiators with antibacterial
activity from the approximate 16000 compounds of the Polar library. This EC50 data will
be essential when setting up a checkerboard assay with the potentiator and amSPC for
detecting synergistic interaction as well as in determining the effective dose for further
toxicity analysis.

Discussion
After characterizing the susceptibility of aminomethyl spectinomycins or amSPCs
to aminoglycoside modifying enzymes in the previous chapter, we wanted to characterize
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Figure 3-6. Scatter plot of the polar library screen data against Escherichia coli
isolate 5 with activity cutoff at 30% growth inhibition
The X-axis has the number of compounds screened for potentiating activity, and the Yaxis represents the % Growth Inhibition exhibited by the compounds, normalized to the
negative control (DMSO).
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Figure 3-7. Scatter plot of the polar library screen data against Escherichia coli
isolate 1 with activity cutoff at 40% growth inhibition
The X-axis has the number of compounds screened for potentiating activity, and the Yaxis represents the % Growth Inhibition exhibited by the compounds, normalized to the
negative control (DMSO).
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Figure 3-8.
Dose-response curve fits of single point hits from Polar library screen
against Escherichia coli isolate 5 and their chemical structures - Part 1
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Figure 3-9. Dose-response curve fits of single point hits from Polar library screen
against Escherichia coli isolate 5 and their chemical structures - Part 2
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Figure 3-10. Dose-response curve fits of single point hits from Polar library screen
against Escherichia coli isolate 5 and their chemical structures - Part 3
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Figure 3-11. Dose-response curve fits of single point hits from Polar library screen
against Escherichia coli isolate 5 and their chemical structures - Part 4
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Figure 3-12. Dose-response curve fits of single point hits of known antibiotic from
Polar library screen against Escherichia coli isolate 5 and their chemical structures Part 1
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Figure 3-13. Dose-response curve fits of single point hits of known antibiotic from
Polar library screen against Escherichia coli isolate 5 and their chemical structures Part 2
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the susceptibility of amSPCs to Gram-negative bacterial resistance mechanisms. We
already had established that amSPCs successfully inhibited the growth of Gram-positive
pathogens like Legionella pneumophila and Neisseria gonorrhea.[133, 135] From our
susceptibility testing of Gram-negative bacteria panel, we know that amSPCs face
significant challenges when it comes to inhibiting the growth of Gram-negative
pathogens like Escherichia coli and Pseudomonas aeruginosa. The Gram-negative cell
envelope presents two complex hurdles for any antibiotic from reaching the high-enough
intracellular concentration to inhibit bacterial growth. The first hurdle is the asymmetric
nature of the lipid bilayer of the outer membrane formed by lipopolysaccharide and
phospholipids, which are interspersed with nonspecific porins. The lipopolysaccharide
offers more rigidity to the bilayer than those lacking the lipopolysaccharide, slowing
down the passive diffusion of hydrophobic drug molecules. The nonspecific porins limit
the permeation power of hydrophilic molecules as they are narrow and allow only very
small polar molecules to pass through them. The second opposing hurdle is the presence
of multidrug efflux pumps, some present in the inner membrane that pump out the drug
from the cytoplasm and function in synergy with those that pump out drugs from the
periplasm.[84, 194] The AcrAB-TolC tripartite efflux pump is an excellent example to
understand the phenomenon.[195] The minimum inhibitory concentration in the
hyperporinated and efflux knock-out strains of Escherichia coli received from Dr.
Zgurskaya’s laboratory indicated efflux. and poor penetration were both contributing to
the lack of growth inhibitory activity of amSPCs.[174, 188] Given the body of literature
exploring new ways to overcome the permeability barrier in Gram-negative bacteria, the
results were not very surprising.
These results and literature evidence of the success of the combination therapy of
antibiotic and non-antibiotic potentiators lead us to look for potentiators of amSPC
activity in Gram-negative bacteria.[189, 191, 196] Ejim et al. and Yarlagadda et al. have
established how potentiating adjuvants can help existing drugs overcome resistance in
bacteria. Based on the high throughput screening and rules of penetration approach
described by Dr. Lewis in his review article, we chose to screen the Polar Library, which
constituted of compounds with logP less than 2, making them more likely to cross the
Gram-negative outer membrane barrier, for potentiators of amSPCs.[64]
The advantages of the cell-based phenotypic screen in drug discovery have been
discussed in detail by Zheng et al. and supported our resolve to use the phenotypic screen
approach for the identification of potentiators of amSPC.[197] We validated our screening
platform using the Bioactive library, which consisted of known antibiotics and FDAapproved drugs combined with our first generation lead amSPC 1950 in bioluminescent
Escherichia coli Xen14. The advantage of using bioluminescent bacteria was that there
was no need to add BacTiter Glo™ to quantify the luminescence for calculating percent
growth inhibition. Escherichia coli Xen14 has a constitutively expressed lux ABCD
operon, and so no external inducer addition was required.[198, 199] This simplified the assay
set up to adding the amSPC to the medium and stamping the selected library, adding the
bioluminescent bacteria, and reading luminescence at the end of 8 hours incubation
period. The advantages of using lux gene expressing bacteria for high throughput
screening in antibacterial drug discovery have been already established for over a
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decade.[200, 201] Upon receiving the multi-drug resistant clinical isolates of Escherichia
coli, we tested their susceptibility to spectinomycin and second-generation lead amSPC
2593 and found them resistant to both. Genome sequencing of the multi-drug resistant
clinical isolates of Escherichia coli and identification of the resistance genes using the
Comprehensive Antibiotic Resistance Database[143] revealed multiple resistance
imparting genes in each clinical isolate. We decided to use the clinical isolates to screen
Polar Library for potentiators instead of bioluminescent strain as the ultimate goal of any
antibacterial drug discovery is to treat clinical infections. Escherichia coli isolate 5 was
chosen because it carried two aadA genes- aadA5 and aadA13, which encode
spectinomycin adenylating enzymes. In chapter 2, we had already seen that aadA13,
which encodes ANT(3")(9), was cloned in an Escherichia coli expression strain and
purified was adenylating and inactivating spectinomycin and amSPC.
Given the highly resistant nature of this clinical isolate, we were not sure of
identifying many non-antibiotic potentiators and decided to also screen the Polar Library
against Escherichia coli isolate 1, which did not have any spectinomycin or amSPC
adenylating enzymes. Since the clinical isolates were not bioluminescent, we switched to
adding BacTiter Glo™ at the end of the 16-hour incubation period to quantify the
luminescence and calculate growth inhibition. Robust Interpretation of Screening
Experiments (RISE) protocol in Pipeline Pilot (Accelrys, v. 8.5) was used to calculate
percent growth inhibition, generate scatter plots and calculate Z' to check the robustness
of the screen.[158] We ended up identifying 17 potentiators of amSPC 2593 against the
Escherichia coli isolate 5 that were confirmed by dose-response curve fitting. We also
identified 79 possible potentiators of amSPC 2593, out of which 24 were known
antibiotics. Dose-response curve fitting for the preliminary potentiator hits against
Escherichia coli isolate 1 was not performed, as we already had confirmed potentiator
hits against the more resistant Escherichia coli isolate 5.
We have identified 12 potentiators of amSPC 2593 and laid the foundation for
developing these hits into a combination therapy. Future work on these confirmed
potentiators will include testing synergy between identified potentiator hits and amSPC,
as the concentration of amSPC was kept constant during our dose-response analysis. The
EC50s generated from the dose-response analysis will be essential in calculating the ideal
potentiator concentration range to be tested for synergy. This combination can again be
tested in the wild type, efflux knock-out, and hyperporinated strains from Dr. Zgurskaya's
laboratory to identify penetration rules in Gram-negative bacteria. The principles and
platforms for antibacterial drug discovery by Dr. Kim Lewis in his review and the panel
of assays used by Yarlagadda et al. will be valuable tools in determining the mechanism
of potentiation action. We realize that there are complexities involved in getting the
amSPC-potentiator combination to the clinics, but we have a clear path in terms of assays
to be performed and cytotoxicity and pharmacokinetics of the combination to be studied.
We believe confirming the ability of the amSPC-potentiator combination to inhibit the
growth of multi-drug resistant clinical isolates is a step in the right direction.
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CHAPTER 4.

CONCLUSIONS

Aminomethyl spectinomycins are modified spectinomycin analogs, and
spectinomycin belongs to the aminocyclitol group of aminoglycosides class of
antibacterials. The reason for pursuing spectinomycin analogs is that aminoglycosides
were designed to treat Gram-negative bacterial infections. However, bacteria have
developed rapidly resistance to most antibiotics’ classes, including major
aminoglycosides, efforts to synthesize newer, more effective aminoglycosides are more
than ever needed. Among aminoglycosides, spectinomycin has a good safety index due to
the lack of ototoxicity and nephrotoxicity usually associated with aminoglycoside usage.
Spectinomycin is also water-soluble and metabolized, and excreted via kidneys, and
hence not subjected to hepatometabolism.[142, 163, 164] Spectinomycins were first modified
by Upjohn company to create Trospectinomycin, which reached stage 3 clinical trials
before being abandoned for commercial reasons in favor of cephalosporins and
macrolides. After the release of the high-resolution crystal structure of the 30 S ribosomal
unit by Dr. Venkatraman and his colleagues, Brunh et al. used the structure-guided
approach to make N -benzyl substitutions to the aminomethyl scaffold first identified by
Upjohn company and synthesized aminomethyl spectinomycins or amSPCs. After
establishing the ability of amSPCs to treat respiratory tract infection by pathogens like
Streptococcus pneumoniae in mice, they checked the ability of amSPCs to inhibit a panel
of respiratory tract pathogens like Legionella pneumophila .and reported that firstgeneration amSPCs successfully inhibited the growth of Legionella pneumophila.[133]
Legionella pneumophila is a Gram-negative respiratory tract pathogen and carries an
aminoglycoside modifying enzyme APH(9)-Ia. These results indicated that amSPCs were
not modified by the aminoglycoside modifying enzymes and inhibited the growth of
Gram-negative bacteria. Given the rapidly rising number of multi-drug resistant (MDR)
and extremely drug-resistant (XDR) Gram-negative bacteria being added to urgent threat
lists of CDC and WHO, identifying drugs that can target Gram-negative bacteria is the
need of the hour.
To address this unmet need for new antibiotics that can target Gram-negative
bacteria, we started this study to characterize the susceptibility of amSPCs to various
resistance factors that Gram-negative bacteria possess. After describing the various
mechanisms of resistance exhibited by bacteria to overcome antibacterial action in
Chapter 1, we characterized the susceptibility of amSPCs to spectinomycin inactivating
aminoglycoside modifying enzymes in chapter 2. The results of microbiological,
biochemical, and structural analysis of APH(9)-Ia and ANT(3”)(9) led us to conclude that
while amSPCs were effective in inhibiting the growth of APH(9)-Ia expressing
Legionella pneumophila and APH(9)-Ia overexpressing efflux knock-out Escherichia coli
strains, they were inactivated by ANT(3”)(9) overexpressing efflux knock-out
Escherichia coli. In the process of this characterization, we designed the spectinomycin
modifying enzyme overexpressing constructs in efflux knocked out Escherichia coli,
which can be used to check the ability of newer amSPC analogs synthesized to overcome
modification by these enzymes. We also developed two unique enzyme assays to check
the ability of APH(9)-Ia and ANT(3”)(9) to phosphorylate and adenylate spectinomycin
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and amSPCs, respectively. In addition, to check the susceptibility of newer amSPCs to
modification, these enzyme activity assays can also be used to identify inhibitors. The
MALDI mass spectrometry-based assay is unique in its ability to quantify phosphorylated
directly or adenylated spectinomycin products instead of relying on measuring the ADP
or pyrophosphate released as a byproduct of the enzyme activity. It is adaptable to a high
throughput screening format and can be used to screen drug libraries to identify inhibitors
of both enzymes. We were also able to solve the crystal structure of the ANT(3”)(9)
enzyme from the clinical isolate of Escherichia coli, which has provided us a good
understanding of the critical interactions occurring with the substrates and cofactors in
the binding site. This information is vital in designing newer amSPC analogs that can
overcome adenylation by the adenylating enzymes with structure-based drug design and
can also be used for the virtual screening of larger libraries to identify inhibitors of these
enzymes.
Although amSPCs were not overcoming the resistance caused by all groups of
aminoglycoside modifying enzymes but just one, in the process of characterization, we
have built platforms that enable the design of newer, more effective amSPC analogs
through structure-based drug design as we now have the crystal structure of ANT(3”)(9)
that was imparting resistance. In addition to characterizing the susceptibility of existing
amSPCs to various resistance mechanisms and creating orthogonal microbiological and
biochemical assays for characterizing newly synthesized analogs, we also created assays
that enable us to identify inhibitors of aminoglycoside modifying enzymes. Given these
modifying enzymes' ubiquitous and ever-adapting nature, a high throughput biochemical
assay and ability to conduct more extensive in silico screens and structure-based drug
design to identify inhibitors is a valuable tool in advancing antibiotic drug discovery
against Gram-negative bacteria
Our goal in Chapter 3 was to identify adjuvants that can potentiate the inhibitory
activity of amSPC in Gram-negative bacteria. We first validated our screening platform
with the Bioactive Library using a bioluminescent strain of Escherichia coli. Upon
receiving multidrug-resistant clinical isolates of Escherichia coli, we sequenced the
genomes of six clinical isolates to identify genes encoding for resistance factors. We
identified multiple genes in each clinical isolate that impart resistance to multiple
antibiotics, including spectinomycin and amSPC. We then screened the Polar Library that
contained molecules with log P < 2 and most likely to cross the outer membrane barrier
of the Gram-negative bacteria against two multi-drug resistant clinical isolates of
Escherichia coli for the potentiators of amSPCs. We identified 43 possible potentiators in
our initial screen, out of which dose-response curve fittings confirmed 17 potentiators
with different scaffolds. These 17 potentiators are now ready to be checked for
synergistic activity with amSPC and can be tested in the hyperporinated and efflux
knockout strains to narrow down their mechanism of action. These potentiators can be
also be tested for their potential in inhibiting the activity of ANT(3”)(9), as they already
enabled amSPC to inhibit the growth of the ANT(3”)(9) encoding clinical isolate.
In addition to characterizing the susceptibility of existing amSPCs to various resistance
mechanisms and creating orthogonal microbiological and biochemical assays for
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characterizing newly synthesized analogs, we also created assays that enable us to
identify inhibitors of aminoglycoside modifying enzymes. Given these modifying
enzymes' ubiquitous and ever-adapting nature, a high throughput biochemical assay and
ability to conduct more extensive in silico screens and structure-based drug design to
identify inhibitors is a valuable tool in advancing antibiotic drug discovery against Gramnegative bacteria. The potentiators of amSPC identified will enable amSPC to gain
inhibitory activity in Gram-negative bacteria, which are becoming increasingly difficult
to treat by a single antibacterial. Using combination therapy also slows down the
development of resistance in bacteria as they target multiple cellular processes
simultaneously. An ideal potentiator and amSPC combination would be an amSPC not
being modified by the aminoglycoside modifying enzymes and a potentiator that will
ensure that the amSPC can penetrate the Gram-negative bacterial membrane to achieve
an optimal intracellular combination to inhibit bacterial growth. The other good
combination of amSPC and potentiator would be an inhibitor of aminoglycoside
modifying enzymes that will help the existing amSPC analogs to regain their growth
inhibitory activity in Gram-negative bacteria.
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